



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(51) International Patent Classification 6 :	C12N 15/31, 1/21, C07K 14/315, 16/12, A61K 39/09, 39/40	A2	(11) International Publication Number: WO 98/21337
(21) International Application Number:	PCT/US97/20586		(43) International Publication Date: 22 May 1998 (22.05.98)
(22) International Filing Date:	12 November 1997 (12.11.97)		
(30) Priority Data:			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(71) Applicant (for all designated States except US):	REGENTS OF THE UNIVERSITY OF MINNESOTA [US/US]; Morrill Hall, 100 Church Street S.E., Minneapolis, MN 55455 (US).		
(71)(72) Applicants and Inventors:	HOSTETTER, Margaret, K. [US/US]; 1832 Kenwood Parkway, Minneapolis, MN 55405 (US). CHENG, Qi [CN/US]; 11240 48th Avenue North, Plymouth, MN 55442 (US). FINKEL, David, J. [US/US]; Apartment 3, 414 S.E. Erie Street, Minneapolis, MN 55414 (US). SMITH, Beverly [US/US]; 1973 Sheridan Avenue South, Minneapolis, MN 55405 (US).		
(74) Agent:	MCCORMACK, Myra, H.; Muetting, Raasch, Gebhardt & Schwappach, P.A., P.O. Box 581415, Minneapolis, MN 55458-1415 (US).		

(54) Title: C3 BINDING PROTEIN OF STREPTOCOCCUS PNEUMONIAE

(57) Abstract

This invention relates to the identification of a human complement C3 binding protein from *Streptococcus pneumoniae* and to its sequence and to methods for its purification and use. The protein binds but does not degrade or cleave C3 and is implicated in *S. pneumoniae* virulence. The protein is recognized by antibodies produced by humans recovering from pneumococcal infection.

PbcA Binds C3 in ELISA



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

C3 BINDING PROTEIN OF *STREPTOCOCCUS PNEUMONIAE***Field of the Invention**

This invention relates to *Streptococcus pneumoniae* and in particular this invention relates to the identification of an *S. pneumoniae* protein that is implicated in *S. pneumoniae* virulence and is capable of binding the complement protein, C3.

Background of the Invention

This application is a continuation in part of a provisional application filed October 16, 1997 (U.S. Serial No. 60/062,473) entitled "C3 BINDING PROTEIN OF *S. PNEUMONIAE*." This application is also a continuation in part of a provisional application filed on September 19, 1997 (U.S. Serial No. 60/059,368), a provisional application filed on February 18, 1997 (U.S. Serial No. 60/038,086) and a provisional application filed on November 12, 1996 (U.S. Serial No. 60/029,444) all entitled "C3 BINDING PROTEIN OF *S. PNEUMONIAE*."

Respiratory infection with the bacterium *Streptococcus pneumoniae* (*S. pneumoniae*) leads to an estimated 500,000 cases of pneumonia and 47,000 deaths annually. Those persons at highest risk of bacteremic pneumococcal infection are infants under two years of age and the elderly. In these populations, *S. pneumoniae* is the leading cause of bacterial pneumonia and meningitis. Moreover, *S. pneumoniae* is the major bacterial cause of ear infections in children of all ages. Both children and the elderly share defects in the synthesis of protective antibodies to pneumococcal capsular polysaccharide after either bacterial colonization, local or systemic infection, or vaccination with purified polysaccharides. *S. pneumoniae* is the leading cause of invasive bacterial respiratory disease in both adults and children with HIV infection and produces hematogenous infection in these patients (Connor et al. *Current Topics in AIDS* 1987;1:185-209 and Janoff et al. *Ann. Intern. Med.* 1992;117(4):314-324).

Individuals who demonstrate the greatest risk for severe infection are not able to make antibodies to the current capsular polysaccharide vaccines. As a result, there are now four conjugate vaccines in clinical trial. Conjugate vaccines consist of pneumococcal capsular polysaccharides coupled to protein carriers or adjuvants in an attempt to boost the antibody response. However, there are other potential problems with conjugate vaccines currently in clinical trials. For example, pneumococcal serotypes that are most prevalent in the United States are different from the serotypes that are most common in places such as Israel, Western Europe, or Scandinavia. Therefore, vaccines that may be useful in one geographic locale may not be useful in another. The potential need to modify currently available capsular polysaccharide vaccines or to develop protein conjugates for capsular vaccines to suit geographic serotype variability entails prohibitive financial and technical complications. Thus, the search for immunogenic, surface-exposed proteins that are conserved worldwide among a variety of virulent serotypes is of prime importance to the prevention of pneumococcal infection and to the formulation of broadly protective pneumococcal vaccines. Moreover, the emergence of penicillin and cephalosporin-resistant pneumococci on a worldwide basis makes the need for effective vaccines even more exigent (Baquero et al. *J. Antimicrob. Chemother.* 1991;28S:31-8).

Several pneumococcal proteins have been proposed for conjugation to pneumococcal capsular polysaccharide or as single immunogens to stimulate immunity against *S. pneumoniae*. Surface proteins that are reported to be involved in adhesion of *S. pneumoniae* to epithelial cells of the respiratory tract include PsaA, PspC/CBP112, and IgA1 proteinase (Sampson et al. *Infect. Immun.* 1994;62:319-324, Sheffield et al. *Microb. Pathogen.* 1992; 13: 261-9, and Wani, et al. *Infect. Immun.* 1996; 64:3967-3974). Antibodies to these adhesins could inhibit binding of pneumococci to respiratory epithelial cells and thereby reduce colonization. Other cytosolic pneumococcal proteins such as pneumolysin, autolysin, neuraminidase, or hyaluronidase are proposed as vaccine antigens because antibodies could potentially block the toxic effects of

these proteins in patients infected with *S. pneumoniae*. However, these proteins are typically not located on the surface of *S. pneumoniae*, rather they are secreted or released from the bacterium as the cells lyse and die (Lee et al. *Vaccine* 1994; 12:875-8 and Berry et al. *Infect. Immun.* 1994; 62:1101-1108). While use of 5 these cytosolic proteins as immunogens might ameliorate late consequences of *S. pneumoniae* infection, antibodies to these proteins would neither promote pneumococcal death nor prevent pneumococcal colonization.

A prototypic surface protein that is being tested as a pneumococcal vaccine is the pneumococcal surface protein A (PspA). PspA is a 10 heterogeneous protein of about 70-140 kDa. The PspA structure includes an alpha helix at the amino terminus, a proline-rich sequence in the mid-portion of the protein, and terminates in a series of choline-binding repeats at the carboxy-terminus. Although much information regarding its structure is available, PspA is not structurally conserved among a variety of pneumococcal serotypes, and its 15 function is entirely unknown (Yother et al. *J. Bacteriol.* 1992;174:601-9 and Yother *J. Bacteriol.* 1994;176:2976-2985). Studies have confirmed the immunogenicity of PspA in animals (McDaniel et al. *Microb. Pathogen.* 1994; 17;323-337). Despite the immunogenicity of PspA, the heterogeneity of PspA, its existence in four structural groups (or clades), and its uncharacterized 20 function complicate its ability to be used as a vaccine antigen.

In patients who cannot make protective antibodies to the type-specific polysaccharide capsule, the third component of complement, C3, and the associated proteins of the alternative complement pathway constitute the first line of host defense against *S. pneumoniae* infection. Because complement 25 proteins cannot penetrate the rigid cell wall of *S. pneumoniae*, deposition of opsonic C3b on the pneumococcal surface is the principal mediator of pneumococcal clearance. Interactions of pneumococci with plasma C3 are known to occur during pneumococcal bacteremia, when the covalent binding of C3b, the opsonically active fragment of C3, initiates phagocytic recognition and 30 ingestion (Johnston et al. *J. Exp. Med* 1969;129:1275-1290, Hasin HE, *J. Immunol.* 1972; 109:26-31 and Hostetter et al. *J. Infect. Dis.* 1984; 150:653-61).

C3b deposits on the pneumococcal capsule, as well as on the cell wall. This method for controlling *S. pneumoniae* infection is fairly inefficient and could be beneficially amplified by the presence of antibodies to surface components of *S. pneumoniae*. There currently exists a strong need for methods and therapies to
5 limit *S. pneumoniae* infection.

Summary of the Invention

The present invention relates to the identification and purification of an about 90 kDa to about 110 kDa (\pm 5 kDa) protein, as determined following
10 electrophoresis on a 15% SDS-PAGE gel. The protein is named PbcA and is isolatable from *S. pneumoniae* strains that are capable of binding to human complement protein C3. The protein, PbcA, comprises an amino terminus containing region comprising SEQ ID NO:1 and is capable of binding but not cleaving or degrading the human complement protein C3. The protein also
15 comprises a proline rich region and in one embodiment is a surface exposed protein of *S. pneumoniae*.

This invention also relates to the production of antibodies specifically recognizing PbcA. In one embodiment the antibodies are polyclonal and in another embodiment the antibodies are monoclonal. The antibodies can
20 be produced by immunizing a mammal with all or a portion of PbcA. In one embodiment, the monoclonal antibodies are rodent derived.

In another aspect of this invention a method is provided for generating an immune response to *S. pneumoniae* *in vivo* comprising the steps of: administering a protein or an immunogenic fragment of a protein from *S. pneumoniae* to an animal wherein the amino terminus containing region of the protein comprises SEQ ID NO:1. In one embodiment, the protein is capable of binding but not cleaving or degrading the human complement protein C3.
25 Preferably, the method further comprises detecting an immune response to *S. pneumoniae* in the mammal. Preferably, the immune response comprises the production of antibodies to *S. pneumoniae*. The animal can be a mouse, rat, chinchilla, a rabbit or a human and the method can further comprise the steps of
30

isolating antibody producing cells from the mammal and preparing monoclonal antibodies to the C3 binding protein.

In yet another aspect of the invention a method is disclosed for obtaining a purified C3 binding protein from *S. pneumoniae* comprising the steps
5 of: obtaining a protein sample from *S. pneumoniae*; precipitating the protein to form a precipitate; applying the precipitate to a Thiopropyl Sepharose 6B affinity chromatography column comprising methylamine-treated C3; and eluting the C3 binding protein from the column using an elution buffer comprising about 20% ethanol. In one aspect of this embodiment the invention relates to C3 binding
10 protein preparable by these methods.

This invention also relates to a C3 binding protein having the sequence of SEQ ID NO:6 and to isolated nucleic acid encoding a C3 binding protein and comprising the DNA sequence of SEQ ID NO:5 and to isolated nucleic acid having the DNA sequence of SEQ ID NO:4.

15 In another aspect of this invention, the invention relates to isolated nucleic acid encoding C3 binding protein of about 90 kDa to about 110 kDa (\pm 5 kDa), in one embodiment, and comprising nucleic acids 1-1500 of SEQ ID NO:5 and to an isolated nucleic acid sequence encoding the C3 binding protein wherein the protein exhibits C3 binding activity and wherein the protein
20 comprises at least 80% nucleic acid homology to nucleic acids 1-1500 of SEQ ID NO:5. Preferably, the nucleic acid homology is at least 95%.

The invention also relates to a C3 binding protein isolatable from *S. pneumoniae* having DNA that is hybridizable to a nucleic acid fragment of at least 500 bp from nucleic acids 1-1500 of SEQ ID NO: 5 under hybridization
25 conditions of about 6X SSC, 5X Denhardt's, 0.5% SDS, 100 μ g/ml denatured, fragment salmon sperm DNA overnight at 65°C and washed in 2X SSC, 0.1%SDS, one time at room temperature for about 10 mn, followed by one time at 65°C for about 15 mn and followed by at least one wash in 0.2 X SSC, 0.1% SDS at room temperature for about 3-5 minutes. Preferably this protein further
30 comprises at least 2 choline binding repeat and still more preferably the protein further comprises at least 2 choline binding repeats.

The invention also relates to peptide fragments of at least 15 bp from SEQ ID NO:5 and to insertion and deletion mutants that do not express PbcA.

In another aspect of this invention, the invention relates to PbcA proteins. In one embodiment the invention relates to an isolated protein comprising SEQ ID NO:1 and at least two choline binding repeats. Preferably the protein is isolated from *S. pneumoniae* and also preferably the protein binds human complement protein C3. In one version of this embodiment, the protein is a recombinant protein or a purified protein from *S. pneumoniae*. Preferably the protein has a molecular weight as determined on a 15% polyacrylamide gel of between about 90 kDa to about 110 kDa and preferably the protein comprises a proline rich region. Additionally the protein can comprise SEQ ID NO:2 or SEQ ID NO:3.

Alternatively, the protein of this invention can comprise SEQ ID NO:6 or the protein can be an isolated protein capable of binding to, but not cleaving or degrading, human complement C3 and wherein the protein comprises SEQ ID NO:1. Preferably the protein is isolated from *S. pneumoniae* and in one embodiment, the protein further comprises a proline rich region. The protein can further comprise SEQ ID NO:2. Preferably the protein has at least about 95% homology to a C3 binding protein from *S. pneumoniae* and also preferably, the protein has a molecular weight as determined on a 15% polyacrylamide gel of between about 90 kDa to about 110 kDa. In one aspect, the isolated protein is a recombinant protein and in another, the protein is isolated from *S. pneumoniae* bacteria.

In another embodiment of the proteins of this invention, the invention relates to a recombinant protein comprising SEQ ID NO:1, wherein the protein has a molecular weight as determined on a 15% polyacrylamide gel of between about 90 kDa to about 110 kDa. Preferably the protein binds human complement protein C3. The protein can further include a proline rich region and preferably the protein does not cleave or degrade human complement protein C3.

In another embodiment of the proteins of this invention, the protein comprises amino acids 1-410 of SEQ ID NO:6.

In yet another embodiment of the proteins of this invention, the invention relates to a protein that binds, but does not cleave or degrade, human complement protein C3, wherein nucleic acid encoding the protein hybridizes to SEQ ID NO:4 under hybridization conditions of 6X SSC, 5X Denhardt, 0.5% SDS, and 100 µg/ml fragmented and denatured salmon sperm DNA hybridized overnight at 65°C and washed in 2X SSC, 0.1% SDS one time at room temperature for about 10 minutes followed by one time at, 65°C for about 15 minutes followed by at least one wash in 0.2XSSC, 0.1% SDS at room temperature for at least 3-5 minutes. Preferably, the protein further comprises SEQ ID NO:1 and optionally, the protein can comprise SEQ ID NO:2 or SEQ ID NO:3. Preferably the protein is at least 15 amino acids in length. Preferably the protein comprises a proline rich region. In one aspect of this embodiment, the protein is a recombinant protein and in another, the protein is a synthetic peptide. In one aspect of this embodiment, the protein is a peptide of at least 15 amino acids from SEQ ID NO:6. The proteins can also be used to create antibody and the proteins of this embodiment can be used to generate antibody capable of specifically binding to the protein. In one embodiment, the antibody is a monoclonal antibody and in another the antibody is a polyclonal antibody. Preferably the monoclonal antibody is at least partially rodent-derived.

This invention also relates to nucleic acid encoding the proteins of this invention. In one embodiment, the nucleic acid of this invention encodes a protein comprising at least two choline binding domains and SEQ ID NO: 1. Preferably the protein encoded by the nucleic acid further comprising a proline rich region. Also preferably, the nucleic acid is isolated from an *S. pneumoniae* genome. Preferably, the nucleic acid is capable of hybridizing to SEQ ID NO:4 and in another embodiment, the protein encoded by the nucleic acid binds to human complement protein C3. In one aspect of this embodiment, the nucleic acid is positioned in a nucleic acid vector. Preferably the vector is an expression

vector and the expression vector directs expression of the protein by the nucleic acid.

In another embodiment of the nucleic acid of this invention, the invention relates to isolated nucleic acid encoding a protein comprising SEQ ID NO:1 and a proline rich region wherein the protein encoded by the nucleic acid binds but does not cleave or degrade human complement C3.

In yet another embodiment, the invention relates to isolated nucleic acid fragment encoding an about 90 kDa to about 110 kDa protein with C3 binding activity, wherein the nucleic acid fragment has at least 80% homology to at least 500 bp from nucleic acids 1-1500 of SEQ ID NO:5 and in another embodiment, the isolated nucleic acid fragment comprises base pairs 1-1500 of SEQ ID NO:5.

The invention also relates to a method for isolating a C3 binding protein from a bacterium comprising the steps of: obtaining a protein sample from a bacterium; applying the sample to a solid support comprising methylamine treated complement protein C3; washing the solid support; and removing a C3 binding protein from the solid support in a solution comprising alcohol wherein the C3 binding protein does not cleave or degrade C3. Preferably the bacterium is *S. pneumoniae* and in another embodiment, the bacterium is *E. coli*. Preferably the solid support comprises an affinity column and preferably the alcohol is ethanol. In one embodiment, the solution comprising alcohol is a buffer comprising 20% ethanol. The invention also relates to C3 binding protein preparable by this method.

The invention also relates to a method for producing an immune response to *S. pneumoniae* comprising the steps of: administering a therapeutically effective amount of at least a portion of a protein to a mammal, wherein the protein binds but does not cleave or degrade human complement protein C3 and, wherein nucleic acid encoding the protein hybridizes to SEQ ID NO:4 under hybridization conditions of 6XSSC, 5X Denhardt, 0.5% SDS, and 100 µg/ml fragmented and denatured salmon sperm DNA, hybridized overnight at 65°C and washed in 2x SSC, 0.1% SDS one time at room temperature for

about 10 minutes followed by one time at 65°C for about 15 minutes followed by at least one wash in 0.2xSSC, 0.1% SDS at room temperature for at least 3-5 minutes; and detecting an immune response to the protein. In one embodiment, the protein is at least 15 amino acids in length and in another the protein is a chimeric protein. In yet another embodiment, the protein comprises SEQ ID NO:1. In another embodiment, the protein has a molecular weight on a 15% polyacrylamide gel of between about 90 kDa to about 110 kDa.

- The invention also relates to a method for reducing *S. pneumoniae* binding to C3 comprising the steps of: administering a therapeutically effective amount of at least a portion of an antibody to a mammal, wherein the antibody specifically recognizes a C3 binding protein from *S. pneumoniae*, and wherein the C3 binding protein is a protein that binds, but does not cleave or degrade human complement protein C3. In one embodiment the antibody comprises at least one variable domain from a monoclonal antibody. In another embodiment, the antibody is administered to the air passages of the mammal or intravenously.

In yet another aspect of this invention, the invention relates to a non-naturally occurring *S. pneumoniae* bacterium that does not express a detectable human complement C3 binding protein, wherein the C3 binding protein comprises SEQ ID NO:1. In one embodiment, the bacterium is the product of an insertion into the gene encoding the C3 binding protein and in another, the bacterium is a product of a deletion in the gene encoding the C3 binding protein. In yet another embodiment, the bacterium is produced by homologous recombination of the gene encoding the C3 binding protein gene with at least a portion of a non-native C3 binding protein gene and in one aspect of this embodiment, the gene encoding at least a portion of the non-native C3 binding protein comprises a mutation within the non-native gene.

Brief Description of the Figures

- Fig. 1 is an amino acid alignment of the choline binding regions of PbcA from *S. pneumoniae* strains CP1200, R6x and 23F.

Fig. 2 is a graph illustrating PbcA binding to human C3 by ELISA.

Fig. 3 summarizes studies to assess the ability of antibody to PbcA to inhibit C3 binding. Figure 3a is a Western blot illustrating the specificity of the antibody preparation for PbcA from CP1200. Figure 3b is a graph illustrating the ability of antibody to PbcA to inhibit C3 binding by ELISA.

Fig. 4 illustrates an exemplary strategy for producing a *pbcA* insertion mutant.

Fig. 5a is a photograph of a Southern blot of DNA from transformed and nontransformed *S. pneumoniae* cells probed with a 1.5kb fragment of *pbcA*. Figure 5b is a photograph of a Southern blot probed with vector pVA891.

Figure 6 is a photograph of Western blot experiments demonstrating that the insertion-duplication mutants of this invention do not produce PbcA protein capable of binding C3 or antibody to PbcA.

Detailed Description of the Preferred Embodiments

The present invention provides a *S. pneumoniae* protein that binds C3. The protein is about 90 kDa to about 110 kDa (\pm about 5 kDa) in mass as observed following electrophoresis on a 15% SDS-PAGE gel and is referred to in this disclosure as "PbcA." PbcA was initially identified using the methods of Example 1. Supernatant proteins from exponentially growing cultures of *S. pneumoniae* were tested by Western blot for their ability to bind to purified human C3 following electrophoresis on a 15% SDS-PAGE gel. In the *S. pneumoniae* strain CP1200, both lysates and supernatants from exponentially growing cells produced a protein band, identified as PbcA, at approximately 90 kDa on 15% SDS-PAGE gels under non-reducing conditions. The protein bound methylamine-treated human C3 (produced as described by Hostetter MK, et al. *J. Inf. Dis.* 150:653-661, 1984), labeled with biotin. PbcA is present in lysates and supernatants from a variety of other *S. pneumoniae* strains. The size of PbcA

varies on a 15% SDS-PAGE gel in *S. pneumoniae* strains from about 90 kDa to about 110 kDa. All PbcA proteins identified thus far are capable of binding, but not cleaving or degrading, purified human complement protein C3. In some strains protein bands of smaller molecular weight are observed.

As will be recognized by those of skill in the art, there are a variety of methods for isolating an individual protein from bacterial supernatants. As one example, the *S. pneumoniae* C3 binding protein, PbcA, is isolated using the methods of Example 2. PbcA, can be purified from other secreted pneumococcal proteins by affinity chromatography. Secreted proteins can be precipitated in a final concentration of 10% trichloroacetic acid (TCA) at 4°C overnight according to Example 2. Resuspended proteins from the TCA precipitate are subjected to affinity column chromatography using methylamine-treated human C3 (*supra*). Elution of the PbcA protein from the affinity column has proven to be difficult. Surprisingly, the PbcA protein from the column can be eluted using an elution buffer comprising an alcohol, preferably ethanol and more preferably about 20% ethanol in the Tris-HCl/NaCl wash buffer. In view of this disclosure, now that PbcA has been identified, those skilled in the art will recognize that other methods could be used to identify, isolate and purify the protein from a variety of C3-binding *S. pneumoniae* without undue experimentation.

Multiple eluates can be pooled to obtain sufficient sample for further analysis. As one example, a sample can be electrophoresed on an SDS-PAGE gel and transferred to nitrocellulose. The protein can be subjected to amino terminal analysis and tryptic digestion for internal peptide sequencing.

The following sequences were obtained from the tryptic digest analysis:

A peptide positioned near the amino terminus:

TENEGSTQAATSSNMAKTEH (SEQ ID NO:1)

And internal regions:

EKPAEQQPQPATQP (SEQ ID NO:2)

SSDSSVGEETLPSSSLK (SEQ ID NO:3)

SEQ ID NO:2 is proline rich and has at least a 75% homology with the *S. pneumoniae* protein PspA over 13 amino acids. Although the proline rich region of PspA aligned with SEQ ID NO:2, neither SEQ ID NO:1 nor SEQ ID NO:3 had any substantial homology to any proteins or peptides previously published in the GenBank database (less than 35% homology). The term "proline rich" as used herein refers to a protein having a stretch of amino acids having at least 5 proline amino acids over a total of about 15 amino acids.

These sequences were confirmed in *S. pneumoniae* strain CP1200 following isolation of the gene and sequencing to obtain the nucleic acid sequence encoding PbcA. In one embodiment of this invention, PbcA is an about 90 kDa to about 110 kDa (\pm 5 kDa, meaning about 85 kDa to about 115 kDa) when *S. pneumoniae* proteins are separated on a 15% SDS-PAGE gel, and in another embodiment, the protein further includes SEQ ID NO:2 and SEQ ID NO:3.

Oligonucleotides corresponding in whole or in part to SEQ ID NOS: 1-3 are useful for identifying and isolating the nucleic acid encoding PbcA (the gene encoding PbcA is termed *pbcA*) and for isolating the *pbcA* and PbcA from a variety of *S. pneumoniae* strains. For example, oligonucleotides corresponding in whole or in part from SEQ ID NOS 1-3 can be used to amplify sequences from genomic DNA isolated from *S. pneumoniae* using standard polymerase chain reaction technology. The amplified sequences can then be directly used as probes or the amplified sequences can be incorporated into a vector for plasmid amplification in a suitable host such as a bacteria or virus and then isolated for sequencing, cloning and for use as probes to detect DNA from libraries of *S. pneumoniae*. The DNA isolated from these procedures is useful in sequencing reactions to obtain the nucleic acid sequence encoding PbcA and to produce vectors, such as expression vectors encoding PbcA as well as for producing recombinant protein. Example 5 provides a preferred method for isolating nucleic acid encoding PbcA.

PbcA can be expressed as a recombinant protein or isolated from *S. pneumoniae* lysates. The *S. pneumoniae* C3 binding protein, PbcA, binds C3

without cleaving or degrading the C3 molecule. A number of bacterial proteins have been reported to bind and to cleave C3 or other complement proteins. For example, a 140 kDa C5a peptidase from group A streptococci cleaves a His₆₇-Lys₆₈ bond at the carboxy terminus of C5a, thereby abolishing the chemoattractant capabilities of the molecule. An enzyme related to the C5a peptidase is also found in group B streptococci (Cleary et al. *Infect. Immun.* 1992; 60:4239-4244 and Bohnsack et al. *Biochim. et Biophys. Acta* 1991; 1079:222-228). Production of an elastase-like enzyme, as can be seen with 24-hour culture supernatants from *Pseudomonas aeruginosa* (Suter et al. *J. Infect. Dis.* 1984; 149:523-31), cleaves C3 into characteristic fragments of 66 kDa and 100 kDa from the C3 α -chain. Like the elastase-like enzyme from *P. aeruginosa*, a 56 kDa neutral cysteine proteinase from *Entamoeba histolytica* cleaves C3a between residues Ser₇₈/Asn₇₉, yielding a defined C3 cleavage fragment of 105 kDa (Reed, et al. *J. Immunol.* 1989; 143:189-95).

C3-cleaving proteinases have been isolated from the membranes of some mammalian cells, including human erythrocytes (p57), neutrophils, and melanoma cells resistant to complement-mediated killing. These proteins are typically serine proteases which yield defined cleavage fragments. For example, p57 cleaves both the α - and β -chains of C3, while the melanoma proteinase cleaves only the α' -chain of C3b, generating a fragment of 35 kDa (Charriaut-Marlangue et al. *Biochem. Biophys. Res. Commun.* 1986; 140:1113-1120 and Ollert et al. *J. Immunol.* 1990; 144:3862-7).

In contrast to these studies, C3 cleavage and/or degradation was not observed with PbcA. PbcA binds C3 without the production of defined cleavage fragments and without evidence of degradation of C3. Although there are microbial precedents for binding and cleaving of complement proteins, there is no previously reported microbial protein that binds C3 non-covalently without degrading or cleaving the molecule. The interaction of C3 and other complement components with proteins from group A and B streptococci, *P. aeruginosa*, and amoebae appears to be quite distinct from what has been observed with *S. pneumoniae*.

Table 1 (SEQ ID NO:4) provides a nucleic acid sequence encompassing the open reading frame encoding a 90 kDa PbcA protein from *S. pneumoniae* strain CP1200. Untranslated 5' and 3' regions are also included in SEQ ID NO:4. The open reading frame encoding PbcA begins at nucleotide 383 and ends with nucleotide 2074. Table 2 is a map providing the amino acids (SEQ ID NO: 6) encoded by the nucleic acids of the major open reading frame from SEQ ID NO:4 (provided in Table 2 as SEQ ID NO:5). The protein predicted from SEQ ID NO:4 contains an amino terminus containing segment with C3 binding activity (upstream from the choline binding repeat region) and a series of choline binding repeats (beginning in SEQ ID NO:5 at about nucleic acid position 1501).

Primers were selected from SEQ ID NO:4 to span the choline binding repeats to assess choline binding repeat variability between strains. The primers used were:

15 5' GCACAACCATCTACTCCA 3' (SEQ ID NO: 7), and
 5' GTACAGGAATTCACTTAACTA 3' (SEQ ID NO:8)

Amplification reactions were performed using DNA from three different *S. pneumoniae* strains: CP1200, R6x and virulent strain 23F (obtained from Dr. Steve Pelton, Boston City Hospital, Boston, MA and identified as isolate "freezer #365"). The results of the amplification studies indicated that the number of choline binding repeats varied depending on the *S. pneumoniae* strain. For example, strain CP1200 contained about 4 repeats while 23F contained about 8 repeats and R6X contained at least about 10 choline binding repeats using the Yother et al. model for choline binding repeat regions (see *infra*). All 25 *S. pneumoniae* strains studied thus far have at least two choline binding repeats. Therefore, in another embodiment of this invention, PbcA is a C3-binding protein from *S. pneumoniae* including SEQ ID NO:1 and at least 2 choline binding repeats.

Choline binding domains are known in the art and a number of 30 references discuss the characteristics of a variety choline binding domains (see, for example, Du Clos et al. *J. Biol. Chem.* 266(4):2167-2171, 1991; Liu et al. *J.*

Biol. Chem. 266(22):14813-14821, 1991; Agrawal et al. *J. Biol. Chem.* 267(35):25352-25358, 1992; and *Nature Structural Biology* 3(4):346-354, 1994). A choline-binding repeat sequence has been identified in *S. pneumoniae* protein PspA as TGWKQENGMWYFYNTDGSMA (see Yother, J. and White, 5 JM, *J. Bacteriology* 176:2976-2985, 1994) Choline binding repeats are associated with membrane binding proteins. Without intending to limit this invention, the strains studied thus far indicate that the virulent strains appear to have more choline binding repeats on average than nonvirulent strains. At the very least it appears that *S. pneumoniae* strains show considerable variability in 10 the choline binding repeat region.

These results are consistent with electrophoretic studies assessing variability in the size of PbcA proteins obtained from a number of *S. pneumoniae* strains. Proteins isolated according to the methods of this invention, when separated by SDS-PAGE, demonstrate some size variability (See Fig. 6) from 15 about 90 kDa to about 110 kDa (\pm 5 kDa). This variability can be attributed, at least in part, to the variability in length of the choline binding repeat region. The proteins of this invention also include a series of peptides at the carboxy terminus of the choline binding repeat region.

Fig. 1 provides a comparison of the amino acid sequence from a 20 region containing the choline binding repeat region from PbcA for three different *S. pneumoniae* strains: CP1200, R6x and 23F(BD23). The amino acids in the boxes represent variations in the 23F (virulent strain BD23) choline binding domain repeat region.

One example of a fragment containing nucleic acid encoding 25 PbcA protein is provided in SEQ ID NO:4. The nucleic acid sequence encoding PbcA in strain CPI200 is provided as SEQ ID NO:5 (see Table 2). In another aspect of this invention, a protein of this invention has the amino acid sequence of SEQ ID NO:6. In one embodiment, a protein of this invention includes amino acids 1-410 of SEQ ID NO:6. In addition, variability between strains has been 30 identified at the amino acid and nucleic acid level. For example, the amino terminus contains some variability and SEQ ID NO:1 may lack the first

threonine residue. In general, PbcA proteins include C3 binding proteins from *S. pneumoniae* that preferably have at least 80% nucleic acid homology within the DNA of the amino terminus-containing region (the region amino-terminal to the choline binding repeats) to SEQ ID NO:5. More preferably, the PbcA proteins
5 have at least 95% homology to the amino terminus-containing region of PbcA and still more preferably the PbcA protein includes SEQ ID NO:1. In another embodiment the PbcA proteins additionally include SEQ ID NO:2 or SEQ ID NO:3.

In one example, the nucleic acid encoding PbcA can be obtained
10 from a variety of *S. pneumoniae* strains. A *S. pneumoniae* genomic library can be prepared using *S. pneumoniae* genomic DNA and in a preferred example, an *S. pneumoniae* genomic library was prepared using the CP1200 strain. Custom libraries can be obtained using a variety of standard methods for library construction. In these studies genomic DNA from *S. pneumoniae* was given to a
15 commercial custom library supplier (Stratagene, LaJolla, CA). In one example, *S. pneumoniae* CP1200 strain genomic DNA was used to prepare the library (Example 5) The results of these studies identified a cloned nucleic acid fragment encoding PbcA. This fragment is useful for identifying PbcA encoding nucleic acid in other *S. pneumoniae* strains and the nucleic acid can be
20 incorporated into vectors including expression vectors, for example to produce recombinant protein using methods such as those described by Sambrook et al. (cited below).

PbcA is preferably encoded by nucleic acid that is capable of hybridizing to at least 500 bp from the amino terminus region of SEQ ID NO: 5
25 under hybridization conditions of about 6X SSC, 5X Denhardt's, 0.5% SDS, 100 µg/ml denatured, fragmented salmon sperm DNA hybridized overnight at 65°C and washed in 2X SSC, 0.1%SDS, one time at room temperature for about 10 mn, followed by one time at 65°C for about 15 mn and followed by at least one wash in 0.2 X SSC, 0.1% SDS at room temperature for about 3-5 minutes. The
30 protein of this invention preferably includes at least two and preferably at least three choline binding repeats.

This invention also relates to nucleic acid fragments of at least 20 bp from SEQ ID NO:5 and to isolated nucleic acid fragments of at least 100 base pairs that hybridize to the *S. pneumoniae* genome or to SEQ ID NO:5 under the hybridization conditions of about 6X SSC, 5X Denhardt's, 0.5% SDS, 100 µg/ml denatured, fragment salmon sperm DNA hybridized overnight at 65°C and washed in 2X SSC, 0.1%SDS, one time at room temperature for about 10 min., followed by one wash at 65°C for about 15 min and followed by at least one wash in 0.2 X SSC, 0.1% SDS at room temperature for about 3-5 minutes.

Preferably the nucleic acid fragments of at least 100 base pairs are part of a nucleic acid sequence that encodes a C3 binding protein that is at about 90 kDa to about 110 kDa. Preferably the nucleic acid fragment encodes a protein having at least two choline binding repeats.

As demonstrated in Example 3, the immunogenicity of PbcA can be studied by testing for the presence of antibodies to PbcA in acute and convalescent sera from patients with culture-proven pneumococcal infection. *S. pneumoniae* proteins can be separated by SDS-PAGE electrophoresis, transferred to nitrocellulose, and incubated with acute or convalescent serum (standard Western blot procedure). Results to detect the presence of antibodies to PbcA in human sera indicated that acute serum did not contain antibodies to any pneumococcal proteins released into the supernatant but that convalescent serum contained antibodies that recognized a band on an acrylamide gel with a molecular weight of PbcA.

PbcA, or fragments of PbcA, can be used to produce antibodies specific to PbcA. The term "specific" is used to mean that when the antibodies to PbcA or fragments thereof are used in Western blots containing PbcA or a PbcA fragment or peptide under standard Western Blot assay conditions, the antibodies recognize only PbcA or its degradation or truncated products. Purified PbcA or fragments, preferably of at least about 15 amino acids in length, can be used to inject laboratory animals for the production of polyclonal and monoclonal antibodies to PbcA. Those skilled in the art will recognize that the methods for producing polyclonal antibodies and for producing monoclonal

- antibodies are known in the art and include the methods disclosed by Harlow et al. (cited below). Purified antibodies can be generated using the isolated protein of this invention, or fragments thereof, without undue experimentation. The antibodies are useful in *in vitro* assays to test for the presence or absence of
- 5 PbcA protein and to test for the ability of the antibodies to block C3 binding as well as in *in vivo* assays to test for the ability of the antibodies to provide passive protection against pneumococcal infection, whether local or systemic. Antibody fragments and chimeric antibodies can be used and the antibodies include at least one variable domain from an antibody specifically recognizing PbcA.
- 10 Moreover, purified proteins, peptides and polypeptides from PbcA can be injected into animals, and later humans, to produce an antibody response to *S. pneumoniae*. As used herein, the terms proteins, peptides and polypeptides are used interchangeably. Therefore, for purposes of this application and as used in the claims, a protein refers to proteins, protein
- 15 fragments, peptides and polypeptides. Methods for introducing the protein, peptide or polypeptide fragment of PbcA to a mammal with an appropriate adjuvant, if necessary, are known in the art. Moreover, all or a portion of PbcA can be produced as an isolated protein or as a recombinant protein. Recombinant proteins can include all or a part of PbcA or can be formed as a chimeric protein.
- 20 As used herein, the term "chimeric protein" refers to a recombinant protein including all or at least 15 amino acids of PbcA and amino acid sequence from at least one other protein positioned amino to, carboxy to, or on either side of the PbcA-derived amino acid. The 15 amino acids of PbcA of the chimeric protein are preferably unique to *S. pneumoniae*-derived proteins. Since patients with
- 25 cleared *S. pneumoniae* infection have convalescent antibodies recognizing PbcA, it is known that the immune system can mount an immune response that includes the production of antibodies to PbcA. Ultimately, PbcA can be used as an immunogen for a pneumococcal vaccine. Further, based on the findings of these studies, antibody produced from the isolated protein, PbcA, can be used in
- 30 Western Blot analyses to determine whether or not a particular *S. pneumoniae*

strain's virulence or avirulence has been associated with the presence or absence of PbcA.

As demonstrated in Example 4, PbcA is implicated in pneumococcal virulence (see Example 4). In this example an avirulent 23F

- 5 pneumococcal isolate was inoculated into the ears of chinchillas. Virulent pneumococcal isolates typically cause otitis media and the influx of leukocytes after injection at concentrations as low as 1×10^2 colony forming units (cfu). In contrast, the avirulent 23F strain was inoculated at concentrations of up to about 1×10^7 cells and even at that level was unable to cause otitis media or
10 inflammation (Giebink et al. *J. Infect. Dis.* 1993; 167:347-355). As discussed in Example 4, studies disclosed here indicate that the avirulent strain reported by Giebink lacked detectable PbcA protein by Western blot. To further study the implications of PbcA on virulence, an insertion/duplication mutation of PbcA was prepared for further study (see Example 8).

- 15 The present invention provides a detailed method of purification of PbcA and studies indicat that PbcA is: (a) immunogenic in man; (b) conserved within the mass range of about 90 kDa to about 110 kDa (as observed on a 15% SDS-PAGE gel) among a variety of pneumococcal serotypes (that is, PbcA has been identified in a variety of serotypes); and (c) absent in an avirulent 23F
20 strain that is incapable of causing otitis media in a chinchilla model.

To demonstrate that PbcA can be detected in an ELISA assay, PbcA coated wells of an ELISA plate were incubated with antibody prepared to purified PbcA from *S. pneumoniae* strain CP1200.

- 25 To demonstrate the ability of PbcA to bind human C3, purified PbcA from CP1200 was used to coat ELISA plates and the coated protein was incubated with methylamine-treated human C3. The binding of methylamine-treated human C3 was assessed using antibody to human C3 conjugated with horeseradish peroxidase (See Example 7). Figure 2 is a graph illustrating the ability of PbcA to bind increasing concentrations of human C3. Specific
30 antibody to PbcA blocked the binding of purified human C3 to PbcA in a dose-dependent fashion. These experiments are detailed in Example 7 and in Figure

3. The Western blot (Figure 3a) demonstrates that the IgG fraction of antibody to PbcA blocked the binding of human C3 to PbcA immobilized on nitrocellulose. The graph (Figure 3b) demonstrates that affinity-purified antibody to PbcA blocked the binding of human C3 to PbcA immobilized on 5 ELISA plates.

A PbcA insertion construct was prepared to interrupt a *pbcA* gene in CP1200 and R6x. An exemplary protocol is provided in Example 8 for producing an exemplary construct suitable for homologous recombination. Figure 4 illustrates a preferred method for preparing an insertion construct to 10 inactivate the *pbcA* gene in *S. pneumoniae*. In these methods, a gene encoding PbcA (a non-native C3 binding protein) is introduced into a cell containing PbcA. The non-native C3 binding protein is homologous to the PbcA in the cell to facilitate homologous recombination and the production of insertional mutations. The presence of the insertion mutant was confirmed by Southern blot 15 for a number of mutated R6X and CP1200 strains following transformation of these strains with the mutating construct pBV004 (see Figure 4). Mutated strains were tested by Southern blot using a 1.5 kb fragment of *pbcA* or vector pVA891 probes. Wild type strain BD23 was not transformed in these studies. Results of the Southern blot experiments are provided in Figure 5.

20 The insertion mutants were tested for their ability to produce PbcA protein using either human C3 or antibody to PbcA (Figure 4). Results indicated that no protein approximating the size of PbcA was detectable in supernatants from the *S. pneumoniae* strains tested on Western blot. Further, neither C3 nor antibody to PbcA bound on the Western blots. Therefore, the 25 mutants are useful to assess functional aspects of PbcA and to serve as a negative control for a variety of PbcA-related experiments.

As noted above, PbcA binds noncovalently to C3. *S. pneumoniae* is generally cleared from the body by the covalent opsonic deposition of C3b on the pneumococcal capsule or cell wall, followed by phagocytosis via C3 30 receptors or Fc receptors on neutrophils or monocytes/macrophages. Nonopsonic (i.e. non-covalent) binding of C3 by pneumococcal surface proteins,

such as PbcA, suggests a mechanism whereby pneumococci can evade opsonization. Without intending to limit the scope of this invention, it is possible that PbcA protein from *S. pneumoniae* could bind C3 *in vivo* and reduce the amount of C3 available for opsonization. Antibodies to PbcA could block 5 the C3-binding effect and restore the opsonic activity of C3 in plasma.

- PbcA can be used in *in vitro* assays to assess the effect of PbcA on cells. For example, in Example 6, purified PbcA was added to cell cultures to study the role of PbcA in *S. pneumoniae* pathogenesis. PbcA can be tested for its toxicity on a variety of cells as well as tested in *in vivo* models for toxicity.
- 10 The results of Example 6 indicated that PbcA, as an intact protein, was toxic to pulmonary epithelial cells and that it stimulated production of the cytokine IL-8 from the epithelial cells. IL-8 is a cytokine that, among other things, stimulates neutrophil migration. Increased concentrations of neutrophils are observed in the lungs of patients with significant *S. pneumoniae* infection in the lung
- 15 passageways. Neutrophils and other white blood cells produce a variety of degradatory enzymes that damage lung tissue in *S. pneumoniae* infection and, based on these studies, lung damage can be the result of enzymatic release from white blood cells, PbcA, or both.

- 20 *S. pneumoniae* can colonize the nasopharynx, infect the lung and ultimately disseminate to the blood, meninges or other sites. Antibody to PbcA can be tested for its ability to reduce the toxicity of the organism to the lung tissue and antibody to PbcA can be tested for its ability to prevent PbcA binding to C3 and to permit C3 to remain available during *S. pneumoniae* infection. Similarly, peptides and polypeptides to PbcA can be administered to mammals
- 25 and used in studies to assess the ability of the immune system to produce antibody to limit *S. pneumoniae* infection.

- 30 Animal models to study *S. pneumoniae* pathogenesis are known in the art. These include, but are not limited to, the chinchilla model for otitis media, the infant rat model for *S. pneumoniae* colonization and bacteremia, the mouse model for colonization, bacteremia and meningeal infection and a rabbit model for studying infection in the meninges. Those of ordinary skill in the art

will recognize that antibodies to PbcA (whether exogenously administered or the product of immunization with all or a part of PbcA) can be tested in these models for their ability to limit or inhibit *S. pneumoniae* infection. Exogenously (i.e., passively) administered antibody can be given through a variety of 5 parenteral routes including, but not limited to, intravenous administration or administration to the air passages of a mammal such as a mouse, chinchilla, rat, rabbit or human.

All references and publications cited herein are expressly incorporated by reference into this disclosure. Particular embodiments of this 10 invention will be discussed in detail and reference has been made to possible variations within the scope of this invention. There are a variety of alternative techniques and procedures available to those of skill in the art which would similarly permit one to successfully perform the intended invention.

15

Example 1
Identification of PbcA from *S. pneumoniae*

10 ml of *S. pneumoniae* strain CP1200 (obtained from D.A. Morrison, University of Illinois, Champagne-Urbana, Illinois and described in 20 Havarstein LF, et al. *Proc. Natl. Acad. Sci. (USA)* 1995;92:11140-11144) was grown to exponential phase ($O.D_{620} \approx 0.3$) in Todd Hewitt broth (Fisher, Pittsburgh, PA) or in a synthetic medium ($O.D_{620} \approx 0.15$, media described by Sicard, A.M. *Genetics* 1964 59:31-44). Pneumococcal cells were pelleted and the supernatant was removed and precipitated with a final concentration of 10% 25 trichloroacetic acid (TCA) at 4°C overnight and samples were electrophoresed on 15% sodium dodecyl sulfate polyacrylamide gels (SDS-PAGE) under non-reducing conditions. Pneumococcal proteins separated by electrophoresis were then transferred to nitrocellulose for Western blotting. After blocking of the Western blot according to standard protocols (Harlow , et al. *Antibodies; A 30 Laboratory manual*. Cold Spring Harbor, NY; Cold Spring harbor Laboratory Press, 1988; 471-510) the blot was incubated with 10 mls of binding buffer containing about 2 μ g/ml of purified human C3 (Hostetter et al. *J. Infect. Dis.*

1994; 150:653-661), labeled with biotin. The blot was washed and incubated with a 1:20,000 dilution of HRP-avidin for 60 minutes at room temperature and developed using the Supersignal™ system (Pierce, Rockford, IL) according to manufacturer's instructions. Purified human C3 bound to a band of about 90
5 kDa under non-reducing and reducing conditions on a 15% SDS-PAGE gel. Similarly, a protein of about 90 kDa was detected when cells were lysed in 5% SDS at room temperature for 30 minutes and following centrifugation, the supernatant was separated on a 15% SDS-PAGE gel.

- Experiments were repeated with the substitution of 2 µg/ml
10 biotinylated C3 after treatment with methylamine (using the methods disclosed in Hostetter, et al. *J. Infect. Dis.* 1984; 150:653-661) to demonstrate that the 90 kDa protein in pneumococcal supernatants and lysates could bind non-opsonic forms of C3. Results again indicated that a 90 kDa protein was recognized by C3. A variety of pneumococcal strains were also tested. C3 bound to PbcA
15 identified in Western blots using supernatants from a variety of virulent pneumococcal strains (serotypes 1,3 [4 strains], 4, 14, 19F)

Example 2
Purification of PbcA

- 20 *S. pneumoniae* CP1200 was grown to mid-exponential phase in 4 liters of Todd Hewitt broth at 37°C. Pneumococcal cells were pelleted by centrifugation at 10,000 x g for 10 minutes. Proteins in the supernatant were precipitated with a final concentration of 10% trichloroacetic acid at 4 °C overnight. The
25 precipitate was resuspended in 40 mls of 100 mM Tris and the final pH adjusted to 7.0. The resuspended proteins were chromatographed on a 1.2 ml column of Thiopropyl Separaose 6B coupled by a disulfide bond to 4 mg methylamine treated human C3. The column was then washed with 40 ml of 100 mM Tris-HCl, pH 7.0 containing 0.5 M NaCl. PbcA was eluted from the column with
30 20% ethanol in the Tris-HCl/NaCl wash buffer. 1 ml. fractions were collected and analyzed by SDS-PAGE and C3 binding assay. A protein of about 90 kDa

to about 110 kDa (+/- 5 kDa) eluted from the C3 affinity column in fractions 2-10.

Multiple eluates from sequential purifications of PbcA from strain 1200 were pooled by precipitation with 90% ethanol to obtain sufficient sample for sequencing and further protein studies. Approximately 80 picomoles of the 5 protein were subjected to amino terminal analysis and tryptic digestion for internal peptide sequencing at the Harvard Microchemical Facility (Cambridge, MA).

Example 3

10 Immunogenicity of PbcA

Immunogenicity of PbcA was assessed by growing 10 ml of *S. pneumoniae* strain CP1200 to exponential phase in Todd Hewitt broth, pelleting the cells, and precipitating proteins from the supernatant with 10% TCA 15 overnight at 4°C. The next day, supernatant proteins were electrophoresed on 15% SDS-PAGE, transferred to nitrocellulose, blocked with skim milk in a standard protocol (Harlow, et al. *supra*) and incubated with a 1:10,000 dilution of acute or convalescent serum from a patient infected with *S. pneumoniae* (Dr. E. Janoff, Minneapolis VA Hospital, Minneapolis, MN). The blot was washed 20 according to methods disclosed in Harlow et al. and incubated with a 1:50,000 dilution of commercially purchased goat anti-human IgG conjugated to horseradish peroxidase (Chemicon, Temecula, CA). The blot was washed and developed with the Supersignal™ system according to manufacturer's instructions.

25 Western blots from these studies demonstrated that acute serum did not contain IgG antibodies to any pneumococcal proteins released into the supernatant but that convalescent serum contained IgG antibodies that recognized a protein of 90 kDa, consistent with the mass of PbcA. These experiments confirmed that PbcA elicited an immune response in humans 30 recovering from *S. pneumoniae* infection and indicated that PbcA is recognized by the human immune system.

Example 4
PbcA is implicated in *S. pneumoniae* virulence

- Virulent pneumococcal isolates typically cause otitis media and
- 5 influx of leukocytes after inoculation in concentrations as low as 1×10^2 (Giebink et al. *J. Infect. Dis.* 1993; 167:347-355). Giebink et al. reported that an avirulent serotype, type 23F, was inoculated into the ears of chinchillas and that inoculum at concentrations of less than about 1×10^7 cells was unable to cause otitis media or inflammation.
- 10 Both the type 23F avirulent strain (GD 23, *supra*) and a type 23F virulent strain (BD23, Dr. Steve Pelton, Boston City Hospital, Boston, MA) were grown to mid-exponential phase in Todd Hewitt broth, the cells were pelleted, and supernatant proteins were precipitated in a final TCA concentration of 10% overnight at 4°C. The following day, the precipitate was resuspended in
- 15 about 1 ml Tris, neutralized to pH 7.0, electrophoresed on 15% SDS-PAGE and then transferred to nitrocellulose. Incubation of the nitrocellulose membrane with 2 µg/ml of biotinylated, methylamine-treated C3 in binding buffer and development of the Western blot with avidin conjugated to horseradish peroxidase detected a PbcA band from a 15% SDS-PAGE gel in both cell lysates
- 20 and supernatants from the virulent type 23F, but PbcA was completely absent in cell lysates and supernatants from the avirulent type 23F. In place of PbcA, a smaller band of 33 kDa was identified. This band may represent a degradation product or a truncated version of PbcA.

25

Example 5
Isolation of nucleic acid encoding PbcA

- Degenerate oligonucleotides were obtained from a commercial supplier based on the sequence of SEQ ID NO:1 and SEQ ID NO:2. The
- 30 oligonucleotides were used to amplify a 1500 bp sequence from CP1200 genomic DNA as template using standard polymerase chain reaction technology. Template, primers, and buffer were added for one 5-minute cycle at 94°C. Then dNTP's and Taq polymerase were added for 30 cycles, as follows: Double

stranded DNA was denatured for 1 min at 94°C, annealed for 1 min at 50°C, and extended for 2 min at 72°C. Final extension was completed in one 8-minute cycle at 72°C. The 1500 bp sequence was random primer labeled using a commercial kit and the sequence was used to screen the CP1200 genomic DNA library prepared under our direction by Stratagene (LaJolla, CA). Hybridization was performed under at least moderate stringency conditions and a variety of hybridization methods are provided in Sambrook et al. (*Molecular Cloning, A Laboratory Manual*, 1989 Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY). Exemplary hybridization conditions used were 65°C hybridization in 6X SSC (1M NaCl) using 5X Denhardt's, 20 mM sodium phosphate, 0.5% SDS and 100 µg/ml denatured sonicated salmon sperm DNA.

Three clones were identified that hybridized to the 1500 bp genomic DNA fragment; two overlapping clones of 4.3 and 5.3 kb, respectively and a third clone of 2.5 kb. Restriction mapping and hybridization studies suggested that the 5.3 kb clone contained an open reading frame encompassing the oligonucleotides from SEQ ID NO:1 and SEQ ID NO:2. A 3.2 kb fragment remaining after HindIII digestion and religation of the 5.3 kb clone is sequenced.

Example 6

**Stimulation of IL-8 Production from Pulmonary Epithelial Cells
in Response to PbcA**

Monolayers of type II pulmonary epithelial cells (A549, American Type Culture Collection (ATCC), Rockville, MD) were incubated for 25 4 hours in culture supernatant (at least about 15µl supernatant diluted in 1 ml. serum free media (50% Hams F12/50% PBS) from exponentially growing *S. pneumoniae* (Pn) laboratory strain (CP1200, *supra*) or clinical isolates grown in Todd Hewitt broth (*supra*). Incubation of the epithelial cell monolayer in the culture supernatant induced the release of about 1169 pg/ml IL-8 while 30 incubation in media alone without culture supernatant and incubation in pneumococcal growth medium alone without culture supernatant was significantly less (p < 0.0001, see table below).

Supernatants from a virulent *S. pneumoniae* clinical isolate, 23F, were also effective at stimulating IL-8 production from pulmonary epithelial cells (about 1,495 pg/ml IL-8). Supernatants from a 23F strain that did not produce otitis media in an animal model did not induce IL-8 release *in vitro*.

5

Increasing the time for which CP 1200 supernatants were incubated with the epithelial monolayer from 4 to 24 hours resulted in an increase in IL-8 production to approximately two times the level of IL-8 obtained after a 4 hour incubation.

10

SDS-PAGE analysis of proteins in CP1200 *S. pneumoniae* supernatants indicated that there a variety of proteins in the supernatants including five discrete bands correlating to identifiable proteins from *S. pneumoniae* that had sizes of about 180 kDa, 90 kDa, 57 kDa 42 kDa and 24 kDa. All five proteins were present in supernatants from the virulent 23F strain during exponential growth, but a band of about 90 kDa to about 110 kDa was absent in supernatants from the avirulent 23F strain.

15

In identical assays, about 150-200 ng of affinity purified PbcA protein elicited at least about 1200 pg/ml IL-8 from pulmonary epithelial cells. This level was similar to that elicited using supernatants from CP1200 and virulent 23F strains after a 4-hour incubation. Thus, not only is PbcA potent in eliciting IL-8 from pulmonary epithelial cells.

20

The combined results from 11 separate assays for IL-8 production are provided below:

	Stimulus	IL-8 Release (pg/ml) mean ± S.E.
25	Medium alone	580 ± 40
	Pneumo supt. Avir 23F(GD23)	471 ± 72
	Pneumo supt. Vir23F(BD23)	1,138 ± 83
30	Pneumo supt. CP1200	1,169 ± 121
	200 ng PbcA(CP1200)	1,679 ± 113
	150 ng PbcA(CP1200)*	1,201
	*assayed once	

Rabbit polyclonal antibody prepared against PbcA was used to determine whether the toxicity and IL-8 production stimulated by PbcA was

inhibited by PbcA-specific antibody as confirmation that the effects observed in these studies were attributable to PbcA.

Example 7

PbcA Binds Human C3

5

C3/PbcA ELISA Binding Assay

Purified PbcA was bound to ELISA 8-well strips (Costar, Cambridge, MA) overnight in binding buffer at room temp at varying concentrations (.5 µg/well and 0 µg/well). Wells were blocked with 5% Milk, 0.05% Tween 20 in PBS and 0.02% azide for 2 hours, washed 3 times with 0.05% Tween 20 in PBS and C3 was added (5 µg/well) in antibody diluent buffer (1% BSA, 1% Tween 20 in PBS) for 2 hours at 37°C. Plates were washed 3 times and incubated with HRP-conjugated goat anti-human C3 (1µg/ml) for 1 hour at 37°C. Plates were washed 3 times, developed with OPD (Zymed protocol) for 30 minutes, and the absorbence was read at A₄₉₀ on an ELISA plate reader.

A standard curve was prepared to assess saturation of PbcA on the plate. Serial dilutions of PbcA protein were added (from 500 ng/well to 0 ng/well) to microtiter wells. Plates were incubated for 1 hour at 37°C with anti-PbcA (1:100), washed, incubated with HRP-conjugated goat anti-rabbit (1:2000) for 1 hour at 37°C. Plates were washed and developed with a 1:10 dilution of OPD developing buffer for 20 minutes at room temperature as per manufacturer's instructions and read at A₄₉₀ on an ELISA plate reader.

25 Binding of C3 was determined by the immobilization of 500 ng
PbcA/well. C3 was added in serial dilutions from 10 µg/well to 0 µg/well and
incubated with immobilized PbcA for 2 hours at 37°C. Goat HRP-conjugated
anti-human C3 (1 µg/well) was added and the absorbance was assessed. Figure
2 shows a dose-response curve for the binding of increasing amounts of C3 to
30 constant amounts of immobilized PbcA.

Results indicated (see Figure 2) that increasing concentrations of C3 bound to 0.5 µg/well PbcA on the plate and saturated with a plateau of 6µg/well.

- Initial blocking experiments were done using the IgG fraction of anti-PbcA polyclonal antibodies (2 to 8-fold molar excess over 500 ng PbcA added per well). The IgG fraction of serum from unimmunized rabbits served as a control. After PbcA protein was bound to the plate overnight and blocked for 2 hours, anti-PbcA antibodies were added for 1 hour at 37°C prior to the addition of C3. Plates were washed, 6 µg C3 was added to each well for 2 hours at 37°C. Plates were then incubated with goat HRP-conjugated anti-human C3 for 1 hour at 37°C then washed and developed for 4 minutes.

Both the IgG fraction of anti-PbcA antibodies and affinity purified antibodies inhibited C3 binding up to 50% while control IgG antibodies did not inhibit C3 binding. Figure 3a (Western blot) demonstrates that the IgG fraction of anti-PbcA blocked the binding of human C3 to PbcA immobilized on nitrocellulose. Figure 3b demonstrates that affinity-purified anti-PbcA blocked the binding of C3 to PbcA by 40-50%, while those antibodies remaining in rabbit serum after the removal of anti-PbcA antibodies had no blocking effect.

20

Example 8
Production of *pbcA* Insertion/Duplication Mutants of *S. pneumoniae*

Generation of a *pbcA* insertion/duplication construct

To generate an insertion/duplication mutant of *pbcA*, a 761 bp fragment was isolated from pDF145 (a plasmid containing *pbcA*) first by digestion with ApoI (New England Biolabs) followed by the addition of DNA Polymerase I, Large (Klenow) Fragment to create a blunt end, and second by digestion with NheI to create a 5' overhang sticky end compatible with XbaI in the vector pVA891. This vector is a streptococcal/*E. coli* shuttle vector that replicated in *E. coli* but not in *S. pneumoniae* (from Dr. Gary Dunny, Dept. Microbiology, University of Minnesota, Minneapolis, MN and described in Macrina FL, et al. *Gene* 25:145-150, 1983). The 761 bp fragment was isolated on

a 0.7% agarose gel. Concurrently, the vector pVA891 was digested with *Cla*I and treated with Klenow to create a blunt end, followed by digestion with *Xba*I to create a 5' sticky end. The 761 bp fragment of *pbcA* was ligated into the pneumococcal vector pVA891 and transformed into competent DH5 α *E. coli*.

5 Transformants were selected by resistance to chloramphenicol and plasmid DNA from 12 clones was cut with EcoRI and SpeI (the 761 fragment introduced a SpeI site). This confirmed the presence of the insert DNA in clones 2-12 and the absence of the insert in the control vector clone. Clone 4 was selected as construct pBV004 and DNA was transformed into unencapsulated laboratory

10 strains R6x and CP1200 and selected by erythromycin (Erm) resistance.

Transformation of Knockout Construct for Insertion/Duplication

Mutagenesis

Pneumococcal strains CP1200 and R6x were grown to OD₅₅₀= 0.2 and stored as frozen stock aliquots. Pneumococcal cultures were diluted 1:100 to 0.002 and grown to OD₅₅₀= 0.02. Competence was induced by the Morrison CSP protocol (Haverstein, L. et al. *Proc. Natl. Acad. Sci. (USA)* 92:11140-11144, 1995). To 100 μ l of cells, competence stimulating peptide (CSP) 100ng, was added along with 500ng to about 1 μ g of construct pBV004 DNA. Cells were incubated for 30-40 minutes in a 37°C water bath with aeration to maintain constant temperature. After transformation, cells were diluted 1:10 in one ml total volume of THB+Y. DNase I (10 μ g/ml) was added and cells were incubated an additional 90 minutes to allow integration. The transformation mixture was diluted 1:10 and 100 μ l of cells were plated in a 4-layer agar overlay procedure as follows: first overlay, 3 mls THB agar; second overlay, 1.5 mls THBY + 1.5 mls THB agar + 100 μ l transformation mixture, incubate 1 hour at 37° C; third overlay, 3 mls THB agar; fourth overlay, 3 mls THB agar + .05 μ g/ml Erythromycin.

Genomic DNA was isolated from wild type R6x, CP1200 and BD23(virulent 23F strain *supra*) strains as well as from insertional mutants in R6x and CP1200. Genomic DNA was digested with EcoRI (which does not

cut within the *pbcA* gene) and electrophoresed in 0.7% agarose, blotted onto nylon membrane and Southern blot performed with digoxigenin-labeled probes.

Referring to Figure 5, on the left are the results of a the Southern blot using the 1.5 kb fragment of *pbcA* as the probe. The probe hybridized with wild-type pneumococcal DNA in a single band and hybridized with two bands in the mutants R62r, R63r, R6x5 and CP1r, as expected.

On the right, the same blot was stripped and reprobed with pVA891 vector DNA. Wild-type DNA does not hybridize with pVA891, while the vector probe hybridizes at the same two bands indicating that the insertion mutagenesis was within the *pbcA* gene.

To confirm that the insertion mutated the gene and disrupted protein production, a Western blot analysis was performed (see Figure 6).

On the left, trichloroacetic acid (TCA) precipitated supernatants from strain R6x and the R62r mutant were electrophoresed on a 7.5% SDS-PAGE gel and blotted with either anti-PbcA antibodies and HRP-goat-anti-rabbit antibodies for detection of PbcA or with biotinylated C3 and HRP-avidin for detection of C3 binding. Insertional mutants did not synthesize PbcA and failed to bind to anti-PbcA antibodies or biotinylated C3. Absence of protein and lack of C3 binding was seen in the mutant compared to wild-type. The PbcA protein from R6x is larger than that of CP1200.

The original CP1200 detected a 90 kDa protein and had a truncated choline binding region due to premature termination. The R6x PbcA protein was about 105 kDa and appears to contain at least 9 choline binding repeats.

25

It will be appreciated by those skilled in the art that while the invention has been described above in connection with particular embodiments and examples, the invention is not necessarily so limited and that numerous other embodiments, examples, uses, modifications and departures from the 30 embodiments, examples and uses may be made without departing from the inventive scope of this application.

TABLE 1
DNA SEQ OF *pbcA* GENE (SEQ ID NO:4)

1 GTAATACGAC TCACTATAGG GCGAATTGGG TACCGGGCCC CCCCTCGAGG
51 TCGACGGTAT CGATAAGCTT ATGCTTGTCA ATAATCACAA ATATGTAGAT
101 CATATCTTGT TTAGGACAGT AAAACATCCT AATTACTTT TAAATATTCT
151 TCCTGAGTTG ATTGGCTTGA CCTTGTGAG TCATGCTTAT GTGACTTTG
201 TTTAGTTT TCCAGTTAT GCAGTTATT TGTATCGACG AATAGCTGAA
251 GAGGAAAAGC TATTACATGA AGTTATAATC CCAAATGGAA GCATAAAGAG
301 ATAAATACAA AATTGATTAT ATATACAGTT CATATTGAAG TAATATAGTA
351 AGGTTAAAGA AAAAATATAG AAGGAAATAA ACATGTTGC ATCAAAAAGC
401 GAAAGAAAAG TACATTATTC AATTGTAAGA TTTAGTATTG GAGTAGCTAG
451 TGTAGCTGTT GCCAGTCTTG TTATGGGAAG TGTGGTTCAT GCGACAGAGA
501 ACGAGGGAAG TACCCAAGCA GCCACITCTT CTAATATGGC AAAGACAGAA
551 CATAGGAAAG CTGCTAAACA AGTCGTCGAT GAATATATAG AAAAAATGTT
601 GAGGGAGATT CAACTAGATA GAAGAAAACA TACCCAAAAT GTCGCCTTAA
651 ACATAAAGTT GACCGCAATT AAAACGAAGT ATTTGCGTGA ATTAAATGTT
701 TTAGAAGAGA AGTCGAAAGA TGAGTTGCCG TCAGAAATAA AAGCAAAGTT
751 AGACCGAGCT TTGAGAAGT TTAAAAAAGA TACATTGAAA CCAGGAGAAA
801 AGGTAGCAGA AGCTAAGAAG AAGGTTGAAG AAGCTAAGAA AAAAGCCGAG
851 GATCAAAAAG AAGAAGATCG TCGTAACTAC CCAACCAATA CTTACAAAAC
901 GCTTGAACCT GAAATTGCTG AGTCGATGT GAAAGTTAAA GAAGCGGAGC
951 TTGAACTAGT AAAAGAGGAA GCTAAAGAAT CTCGAAACGA GGGCACAATT
1001 AAGCAAGCAA AAGAGAAAGT TGAGAGTAAA AAAGCTGAGG CTACAAGGTT
1051 AGAAAACATC AAGACAGATC GTAAAAAAGC AGAAGAAGAA GCTAAACGAA
1101 AACCAAGATGC TAAGTTGAAG GAAGCTAATG TAGCGACTTC AGATCAAGGT

TABLE 1 (CONTD.)
DNA SEQ OF *pbcA* GENE (SEQ ID NO:4)

1151 AAACCAAAGG GGCGGGCAAA ACGAGGAGTT CCTGGAGAGC TAGCAACACC
 1201 TGATAAAAAA GAAAATGATG CGAAGTCTTC AGATTCTAGC GTAGGTGAAG
 1251 AAACTCTTCC AAGCTCATCC CTGAAATCAG GAAAAAAGGT ACCAGAACGCT
 1301 GAGAAGAAGG TTGAAGAAGC TGAGAAAAAA GCCAAGGATC AAAAAGAAGA
 1351 AGATCGCCGT AACTACCCAA CCAATACTTA CAAAACGCTT GACCTTGAAA
 1401 TTGCTGAGTC CGATGTGAAA GTTAAAGAAG CGGAGCTTGA ACTAGTAAAA
 1451 GAGGAAGCTA AGGAACCTCG AGACGAGGAA AAAATTAAAGC AAGCAAAAGC
 1501 GAAAGTTGAG AGTAAAAAAG CTGAGGCTAC AAGGTTAGAA AACATCAAGA
 1551 CAGATCGTAA AAAAGCAGAA GAAGAAGCTA AACGAAAAGC ACCAGAAGAA
 1601 GATAAAGTTA AAGAAAAACC AGCTGAACAA CCACAACCAG CGCCGGCTAC
 1651 TCAACCAGAA AAACCAGCTC CAAAACCAGA GAAGCCAGCT GAACAACCAA
 1701 AAGCAGAAAA AACAGATGAT CAACAAGCTG AAGAAGACTA TGCTCGTAGA
 1751 TCAGAAGAAG AATATAATCG CTTGACTCAA CAGCAACCGC CAAAAACTGA
 1801 AAAACCAGCA CAACCATCTA CTCCAAAAAC AGGCTGGAAA CAAGAAAACG
 1851 GTATGTGGTA CTTCTACAAT ACTGATGGTT CAATGGCAAC AGGATGGCTC
 1901 CAAAACAACG GTTCATGGTA CTATCTAAAC GCTAATGGTG CTATGGCGAC
 1951 AGGATGGCTC CAAAACAATG GTTCATGGTA CTATCTAAAC GCTAATGGTT
 2001 CAATGGCAAC AGGATGGCTC CAAAACAATG GTTCATGGTA CTACCTAAAC
 2051 GCTAATGGTG CTATGGCGAC AGGATAGCTC CAATACAATG GTTCATGGTA
 2101 CTACCTAAAC AGCAATGGCG CTATGGCGAC AGGATGGCTC CAATACAATG
 2151 GCTCATGGTA CTACCTCAAC GCTAATGGTG ATATGGCGAC AGGATGGCTC
 2201 CAAAACAACG GTTCATGGTA CTACCTCAAC GCTAATGGTG ATATGGCGAC
 2251 AGGATGGCTC CAATACAACG GTTCATGGTA TTACCTCAAC GCTAATGGTG
 2301 ATATGGCGAC AGGTTGGGTG AAAGATGGAG ATACCTGGTA CTATCTTGAA
 2351 GCATCAGGTG CTATGAAAGC AAGCCAATGG TTCAAAGTAT CAGATAAATG
 2401 GTACTATGTC AATGGCTAG GTGCCCTTGC AGTCAACACA ACTGTAGATG
 2451 GCTATGGAGT CAATGCCAAT GGTGAATGGG TAAACTAAAC CTAATATAAC

TABLE 1 (CONTD.)**DNA SEQ OF *pbcA* GENE (SEQ ID NO:4)**

2501 TAGTTAATAC TGACTTCCTG TAAGAACTTT TTAAAGTATT CCCTACAAAT
2551 ACCATATCCT TTCAGTAGAT AATATACCT TGTAGGAAGT TTAGATTAAA
2601 AAATAACTCT GTAATCTCTA GCCGGATTAA TAGCGCTAGA GACTACGGAG
2651 TTTTTTGAT GAGGAAAGAA TGGCGGCATT CAAGAGACTC TTAAAGAGAG
2701 TTACGGTTT TAAACTATTA AGCCTCTCC AATTGCAAGA GGGCTTCAAT
2751 CTCTGCTAGG GTGCTAGCTT GCGAAATGGC TCCACGGAGT TTGGCAGCGC
2801 CAGATGTTCC ACGGAGATAG TGAGGAGCGA GGCGCGGAA TTCACGAAC
2851 GCGACGTTT CTCCTTGAG GTTAATCAAT CGTTTCAGGA ATTCCGGAAT
2901 TCCGGAATTG CGGAATTCCG GAATTCCGGA ATTCTGCAG CCCGGGGGAT
2951 CCACTAGTTC TAGAGCGGCC GCCACCGCGG TGGAGCTCCA GCTTTGTT
3001 CCTTGTGA GGGTTAATTT CGA

TABLE 2
pbcA DNA (SEQ ID NO:5)
PbcA PROTEIN (SEQ ID NO:6)

1	ATGTTGCATCAAAAGCGAAGAAAAGTACATTATTCAATTGTAAATTTAGTATTGGA TACAAAACGTAGTTTCGCTTCTTTCATGTAATAAGTTAACGCAATTAAATCATAACCT	60
a	M F A S K S E R K V H Y S I R K F S I G -	
61	GTAGCTAGTGTAGCTGTTGCCAGTCTGTATGGGAAGTGTGGTTCATGCGACAGAGAAC CATCGATCACATCGACACGGTCAGAACAAATACCCCTCACACCAAGTACGCTGTCTCTG	120
a	V A S V A V A 'S L V M G S V V H A T E N -	
121	GAGGGAAAGTACCCAAGCAGGCCACTTCCTCTAATATGGCAAAGACAGAACATAGGAAAGCT CTCCCCITCATGGGTTCGTCGGTGAAGAAGATTATACCGTTCTGTCTGTATCCCTTCGA	180
a	E G S T Q A A T S S N M A K T E H R K A -	
181	GCTAAACAAGTCGTCGATGAATATATAGAAAAAATGTTGAGGGAGATTCAACTAGATAGA CGATTGTTAGCAGCTACTTATATATCTTTTACAACCTCCCTCAAGTTGATCTAICT	240
a	A K Q V V D E Y I E K M L R E I Q L D R -	
241	AGAAAACATAACCCAAAATGTCGCCCTAACATAAAGTTGAGCGCAATTAAAACGAAGTAT TCTTTGTATGGGTTTACAGCGGAATTGTATTCAACTCGCGTTAATTGCTCAIA	300
a	R K H T Q N V A L N I K L S A I K T K Y -	
301	TTGCGTGAAATTAAATGTTTAGAAGAGAAGTCGAAGATGAGTTGCCGTCAAGAAATAAA AACCGCACTTAATTACAAAATCTCTCTCAGCTTCTACTCAACGGCAGCTTIAATT	360
a	L R E L N V L E E K S K D E L P S E I K -	
361	GCAAAGTTAGACCCAGCTTTGAGAAGTTAAAAAGATACTTGAAACCAGGAGAAAAG CGTTCAATCTGCGTCGAAACTCTCAAAATTTCATGIAACTTTGGCTCTTTTC	420
a	A K L D A A F E K F K K D T L K P G E K -	
421	GTAGCAGAAGCTAAGAAGAAGTTGAAGAAGCTAAGAAGAAAAGCCGAGGATCAAAAGAA CATCGTCTCGATTCTCTCCACTTCTCGATTCTTTTCGGCTCCTAGTTTCTT	480
a	V A E A K K K V E E A K K K A E D Q K E -	
481	GAAGATCGTCGTAACTACCAACCAACTTACAAAACGTTGAACTTGAATTGCGAG CTTCTAGCAGCATGATGGGTTGGTATGAAATGTTTGCAGACTTGAACCTTAACGACTC	540
a	E D R R N Y P T N T Y K T L E I E I A E -	
541	TTCGATGTGAAGTTAAAGAAGCGGAGCTGAACTAGTAAAGAGGAAGCTAAAGAAATT AAGCTACACTTCAATTCTCGCCCTCGACTTGTATTTCTCCTTCGATTTCTAGA	600

TABLE 2 (CONTD.)
***pbcA* DNA (SEQ ID NO:5)**
PbcA PROTEIN (SEQ ID NO:6)

a	F D V K V K E A E L E L V K E E A K E S -
601	CGAAACGAGGGCACAATTAAAGCAAGCAAAAGAGAAAAGTTGAGAGTAAAAAGCTGAGGCT GCTTGCTCCCGTGTAAATCGTCGTTCTCTTCAACTCTCATTTTCGACTCCGA + 660
a	R N E G T I K Q A K E K V E S K K A E A -
661	ACAAGGTTAGAAAACATCAAGACAGATCGTAAAAAGCAGAAGAAGAAGCTAACGAAA TGTCCAATCTTTGTAGTCTGTCTAGCATTTTCGTCCTCTTCGATTTGCTTT + 720
a	T R L E N I K T D R K K A E E E A K R K -
721	GCAGATGCTAAGTTGAAGGAAGCTAATGTAGCGACTTCAGATCAAGGTAACCAAAGGG CGTCTACGATTCAACTTCCCTCGATTACATCGCTGAAGTCTAGTCCATTGGTTCCCC + 780
a	A D A K L K E A N V A T S D Q G K P K G -
781	CGGGCAAAACGAGGAGTTCCCTGGAGAGCTAGCAACACCTGATAAAAAAGAAAATGATGCG GCCCGTTTGCTCCTCAAGGACCTCTCGATCGTTGGACTATTTTCTTTACTACGC + 840
a	R A K R G V P G E L A T P D K K E N D A -
841	AAGTCCTCAGATTCTAGCGTAGGTGAGAAAATCTTCCAGCTCATCCCTGAAATCAGGA TTTCAAGTCTAAGATCGCATCCACTCTTGAGAAGGTTCGAGTAGGGACTTTAGTCT + 900
a	K S S D S S V G E E T L P S S S L K S G -
901	AAAAGGTACAGAAGCTGAGAAGAAGGTTGAAGAAGCTGAGAAAAAGCCAGGATCAA TTTTCCATCGTCCTCGACTCTTCTCCAACCTCTCGACTCTTTTCGGTTCTAGTT + 960
a	K K V A E A E K K V E E A E K K A K D Q -
961	AAAGAAGAAGATCGCCGTAACCTACCCACCAATACCTACAAACGCTTGACCTTGAAATT TTTCTCTCTAGCGGCATTGATGGGTTGGTATGAATGTTGCGAACTGGAACCTTAA + 1020
a	K E E D R R N Y P T N T Y K T L D L E I -
1021	GCTGAGTCGGATGTGAAAGTAAAGAAGCGGGAGCTTGAACACTAGTAAAAGAGGAAGCTAAG CGACTCAGGCTACACTTCATTTCTCGCTCGACTTGTATCTCTCTCGATTCCTTCGATTC + 1080
a	A E S D V K V K E A E L E L V K E E A K -
1081	GAACCTCGAGAGGGAAAAAAATTAGCAAGCAAAAGCGAAAGTTGAGAGTAAAAAGCT CTTGGAGCTGCTCCCTTTAATCGTTGCTTTCGCTTCAACTCTCATTTTCGAA + 1140
a	E F R D E E K I K Q A K A K V E S K K A -
1141	GGGGCTACAGGTTAGAAACATCGAGAGATCGTAAAAAGCAGAAGAAGAAGCTAAA CTCCGATGTTCCAATCTTTGTAGTCTGTCTAGCATTTTCGTCCTCTCTCGATTT + 1200
a	E A T R L E N I E T D R K K A E E E A K -

TABLE 2 (CONTD.)
pbcA DNA (SEQ ID NO:5)
PbcA PROTEIN (SEQ ID NO:6)

	CGAAAAGCAGCAGAAGAAATAAAAGTAAAGAAAAACCAAGCTGAACAACCACAAACACCG		
1201	GCTTTTCGICGTCTCTCTATTCATTTCAATTCTTTGGTCGACTTGTGGTGTGGTCGC		1260
a	R K A A E E D K V K E K P A E Q P Q P A -		
1261	CCGGCTACTCAACCAGAAAAACCAAGCTCCAAAACCAAGAGAAGCCAGCTGAACACACAAAA		
	GGCCGATGAGTTGGTCTTTGGTCGAGGTTTGTCGACTCTCGGTGACTTGTGGTTT		1320
a	P A T Q P E K P A P K P E K P A E Q P K -		
1321	GCAGAAAAAACAGATGATCAACAAGCTGAAGAAGACTATGCTCGTAGATCAGAAGAAGAA		
	CGTCTTTTGTCTACTAGTTGTCGACTCTCTGATAACGAGCATCTAGCTTCTTCTT		1380
a	A E K T D D Q Q A E E D Y A R R S E E E -		
1381	TATAATCGCTTGACTCAACAGCAACGCCAAAAACTGAAAAACCAAGCACAAACCATCTACT		
	ATATTAGCGAAGTGAGTTGTCGTTGGCGTTTGACTTTGGTCGTTGGTAGATGA		1440
a	Y N R L T Q Q Q P P K T E K P A Q P S T -		
1441	CCAAAAAACAGGCTGGAAACAAGAAAAACGGTATGTGGTACTCTACAATACTGATGGTCA		
	GGTTTTGTCCGACCTTGTCTTGGCATAACACCATGAAGATGTTATGACTACCAAGT		1500
a	P K T G W K Q E N G M W Y F Y N T D G S -		
1501	ATGGCAACAGGATGGCTCCAAAACAACGGTCAATGGTACTATCTAAACGCTAATGGTCT		
	TACCGTTGTCCCTACCGAGGTTTGTTGCAAGTACCATGATAGATTGCGATTACCAAGT		1560
a	M A T G W L Q N N G S W Y Y I N A N G A -		
1561	ATGGCCACAGGATGGCTCCAAAACAATGGTCAATGGTACTATCTAAACGCTAATGGTCA		
	TACCGCTGTCCCTACCGAGGTTTGTTGCAAGTACCATGATAGATTGCGATTACCAAGT		1620
a	M A T G W L Q N N G S W Y Y I N A N G S -		
1621	ATGGCAACAGGATGGCTCCAAAACAATGGTCAATGGTACTACCTAAACGCTAATGGTCT		
	TACCGTTGTCCCTACCGAGGTTTGTTGCAAGTACCATGATGGATTGCGATTACCAAGT		1680
a	M A T G W L Q N N G S W Y Y I N A N G A -		
1681	ATGGCGACAGGATAG	1695	
	TACCGCTGTCCCTAC		
a	M A T G * -		

WHAT IS CLAIMED IS:

1. An isolated protein comprising SEQ ID NO:1 and at least two choline binding repeats.
2. The protein of claim 1 wherein the protein is isolated from *S. pneumoniae*.
3. The protein of claim 1 wherein the protein binds human complement protein C3.
4. The protein of claim 1, wherein the protein is a recombinant protein.
5. The protein of claim 1 having a molecular weight as determined on a 15% polyacrylamide gel of between about 90 kDa to about 110 kDa.
6. The protein of claim 1 further comprising a proline rich region.
7. The protein of claim 1 further comprising SEQ ID NO:2 or SEQ ID NO:3.
8. An isolated protein comprising SEQ ID NO:6.
9. An isolated protein capable of binding to, but not cleaving or degrading, human complement C3 and wherein the protein comprises SEQ ID NO:1.
10. The protein of claim 9 wherein the protein is isolated from *S. pneumoniae*.
11. The protein of claim 9 further comprising a proline rich region.

12. The protein of claim 9 further comprising SEQ ID NO:2.
13. The protein of claim 9 having at least about 95% homology to a C3 binding protein from *S. pneumoniae*.
14. The protein of claim 9 having a molecular weight as determined on a 15% polyacrylamide gel of between about 90 kDa to about 110 kDa.
15. The protein of claim 9, wherein the protein is a recombinant protein.
16. A recombinant protein comprising SEQ ID NO:1, wherein the protein has a molecular weight as determined on a 15% polyacrylamide gel of between about 90 kDa to about 110 kDa.
17. The protein of claim 16 wherein the protein binds human complement protein C3.
18. The protein of claim 16 further comprising a proline rich region.
19. The protein of claim 17, wherein the protein does not cleave or degrade human complement protein C3.
20. A protein comprising amino acids 1-410 of SEQ ID NO:6.
21. A protein that binds, but does not cleave or degrade, human complement protein C3, wherein nucleic acid encoding the protein hybridizes to SEQ ID NO:4 under hybridization conditions of 6XSSC, 5X Denhardt, 0.5% SDS, and 100 µg/ml fragmented and denatured salmon sperm DNA hybridized overnight at 65°C and washed in 2X SSC, 0.1% SDS one time at room temperature for about 10 minutes followed by one time at, 65°C for about 15 minutes followed

by at least one wash in 0.2XSSC, 0.1% SDS at room temperature for at least 3-5 minutes.

22. The protein of claim 21 further comprising SEQ ID NO:1.
23. The protein of claim 21 further comprising SEQ ID NO:2 or SEQ ID NO:3.
24. The protein of claim 21 wherein the protein is at least 15 amino acids in length.
25. The protein of claim 21, wherein the protein is a recombinant protein.
26. The protein of claim 21 further comprising a proline rich region.
27. The protein of claim 21, wherein the protein is a synthetic peptide.
28. The protein of claim 21, wherein the protein is a peptide of at least 15 amino acids from SEQ ID NO:6.
29. Antibody capable of specifically binding to the protein of claim 21.
30. The antibody of claim 29, wherein the antibody is a monoclonal antibody.
31. The antibody of claim 29, wherein the antibody is a polyclonal antibody.
32. The antibody of 30, wherein the antibody is rodent-derived.
33. Nucleic acid encoding a protein comprising at least two choline binding domains and SEQ ID NO: 1.

34. The nucleic acid of claim 33 further comprising a proline rich region.
35. The nucleic acid of claim 33 isolated from an *S. pneumoniae* genome.
36. The nucleic acid of claim 33 capable of hybridizing to SEQ ID NO:4.
37. The nucleic acid of claim 33 wherein the protein encoded by the nucleic acid binds to human complement protein C3.
38. The nucleic acid of claim 33 in a nucleic acid vector.
39. The nucleic acid of claim 33 wherein the vector is an expression vector.
40. The nucleic acid of claim 38 in a cell.
41. The nucleic acid of claim 40 wherein the cell is a bacterium.
42. A bacterium expressing a recombinant protein according to claim 21.
43. The nucleic acid of claim 39 in a cell.
44. Protein produced by the nucleic acid of claim 43.
45. Isolated nucleic acid encoding a protein comprising SEQ ID NO:1 and a proline rich region wherein the protein encoded by the nucleic acid binds but does not cleave or degrade human complement C3.
46. An isolated nucleic acid fragment encoding an about 90 kDa to about 110 kDa protein with C3 binding activity, wherein the nucleic acid fragment has at least 80% homology to at least 500 bp from nucleic acids 1-1500 of SEQ ID NO:5.

47. An isolated nucleic acid fragment comprising base pairs 1-1500 of SEQ ID NO:5.

48. A method for isolating a C3 binding protein from a bacterium comprising the steps of:

obtaining a protein sample from a bacterium;
applying the sample to a solid support comprising methylamine treated complement protein C3;
washing the solid support; and
removing a C3 binding protein from the solid support in a solution comprising alcohol;

wherein the C3 binding protein does not cleave or degrade C3.

49. The method of claim 48 wherein the bacterium is *S. pneumoniae*.

50. The method of claim 48 wherein the bacterium is *E. coli*.

51. The method of claim 48 wherein the solid support comprises an affinity column.

52. The method of claim 48 wherein the alcohol is ethanol.

53. The method of claim 52 wherein the solution comprising alcohol is a buffer comprising 20% ethanol.

54. C3 binding protein preparable by the method of claim 48.

55. A method for producing an immune response to *S. pneumoniae* comprising the steps of:

administering a therapeutically effective amount of at least a portion of a protein to a mammal, wherein the protein binds but

does not cleave or degrade human complement protein C3 and, wherein nucleic acid encoding the protein hybridizes to SEQ ID NO:4 under hybridization conditions of 6XSSC, 5X Denhardt, 0.5% SDS, and 100 µg/ml fragmented and denatured salmon sperm DNA, hybridized overnight at 65°C and washed in 2x SSC, 0.1% SDS one time at room temperature for about 10 minutes followed by one time at 65°C for about 15 minutes followed by at least one wash in 0.2xSSC, 0.1% SDS at room temperature for at least 3-5 minutes; and detecting an immune response to the protein.

56. The method of claim 55 wherein the protein is at least 15 amino acids in length.
57. The method of claim 55 wherein the protein is a chimeric protein.
58. The method of claim 55 wherein the protein comprises SEQ ID NO:1.
59. The method of claim 55 wherein the protein has a molecular weight on a 15% polyacrylamide gel of between about 90 kDa to about 110 kDa.
60. A method for reducing *S. pneumoniae* binding to C3 comprising the steps of: administering a therapeutically effective amount of at least a portion of an antibody to a mammal, wherein the antibody specifically recognizes a C3 binding protein from *S. pneumoniae*, and wherein the C3 binding protein is a protein that binds, but does not cleave or degrade human complement protein C3.
61. The method of claim 60 wherein the antibody comprises at least one variable domain from a monoclonal antibody.

62. The method of claim 60 wherein the antibody is administered to the air passages of the mammal.
63. The method of claim 60 wherein the antibody is administered intravenously to a mammal.
64. A non-naturally occurring *S. pneumoniae* bacterium that does not express a detectable human complement C3 binding protein, wherein the C3 binding protein comprises SEQ ID NO:1.
65. The bacterium of claim 64 wherein the bacterium is the product of an insertion into the gene encoding the C3 binding protein.
66. The bacterium of claim 64 wherein the bacterium is a product of a deletion in the gene encoding the C3 binding protein.
67. The bacterium of claim 64 produced by homologous recombination of the gene encoding the C3 binding protein gene with at least a portion of a non-native C3 binding protein gene.
68. The method of claim 67 wherein the gene encoding at least a portion of the non-native C3 binding protein comprises a mutation within the non-native gene.

//

1
 1200 DRWKQENG~~MW~~ YFYNTDGSMA TGWLQNNGSW YYLNANGAMA TGWLQNNGSW 50
 r6x ---KQENG~~MW~~ YFYNTDGSMA TGWLQNNGSW YYLNANGAMA TGWLQNNGSW
 23f --~~LETR~~NG~~MW~~ YFYNTDGSMA TGWLQNNGSW YYLN~~S~~NGAMA TGWLQNNGSW

51
 1200 YYLNANGSMA TGWLQNNGSW YYLNANGAMA TGWLQYNGSW YYLNSNGAMA 100
 r6x YYLNANGSMA TGWLQNNGSW YYLNANGAMA TGWLQYNGSW YYLNSNGAMA
 23f YYLNANGSMA TGWLQNNGSW YYLNANGSMA TGWLQYNGSW YYLN~~S~~NGAMA

101
 1200 TGWLQYNGSW YYLNANGDMA TGWLQNNGSW YYLNANGDMA TGWLQYNGSW 150
 r6x TGWLQYNGSW YYLNANGDMA TGWLQNNGSW YYLNANGDMA TGWLQYNGSW
 23f TGWLQNNGSW YYLNANGDMA TGWLQNNGSW YYLNANGDMA TGWLQYNGSW


151
 1200 YYLNANGDMA TGWVKDGDTW YYLEASGAM~~X~~ ASQWFKVSDK WYYVNGSGAL 200
 r6x YYLNANGDMA TGWVKDGDTW YYLEASGAM~~X~~ ASQWFKVSDK WYYVNGSGAL
 23f YYLNANGDMA TGWVKDGDTW YYLEASGAM~~X~~ ASQWFKVSDK WYYVNGSGAL

201 223
 1200 AVNTTVDGYG VNANGEW*TK H*Y
 r6x AVNTTVDGYG VNANGEW*TK P--
 23f AVNTTVDGYG VNANGEW*TK PNT

Fig. 1

Fig. 2

PbCA Binds C3 in ELISA



Anti-PbCA Inhibits Binding of C3 in Western and ELISA





Fig. 3

a






Fig. 5




Fig. 6



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(51) International Patent Classification 6 : C12N 15/31, 1/21, C07K 14/315, 16/12, A61K 39/09, 39/40 // (C12N 1/21, C12R 1:46)		A3	(11) International Publication Number: WO 98/21337
			(43) International Publication Date: 22 May 1998 (22.05.98)
(21) International Application Number: PCT/US97/20586		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 12 November 1997 (12.11.97)			
(30) Priority Data:			
60/029,444	12 November 1996 (12.11.96)	US	
60/038,086	18 February 1997 (18.02.97)	US	
60/059,368	19 September 1997 (19.09.97)	US	
60/062,473	16 October 1997 (16.10.97)	US	
(71) Applicant (for all designated States except US): REGENTS OF THE UNIVERSITY OF MINNESOTA [US/US]; Morrill Hall, 100 Church Street S.E., Minneapolis, MN 55455 (US).			
(71)(72) Applicants and Inventors: HOSTETTER, Margaret, K. [US/US]; 1832 Kenwood Parkway, Minneapolis, MN 55405 (US). CHENG, Qi [CN/US]; 11240 48th Avenue North, Plymouth, MN 55442 (US). FINKEL, David, J. [US/US]; Apartment 3, 414 S.E. Erie Street, Minneapolis, MN 55414 (US). SMITH, Beverly [US/US]; 1973 Sheridan Avenue South, Minneapolis, MN 55405 (US).			
(74) Agent: MCCORMACK, Myra, H.; Mueting, Raasch, Gebhardt & Schwappach, P.A., P.O. Box 581415, Minneapolis, MN 55458-1415 (US).			

(54) Title: C3 BINDING PROTEIN OF *STREPTOCOCCUS PNEUMONIAE*

(57) Abstract

This invention relates to the identification of a human complement C3 binding protein from *Streptococcus pneumoniae* and to its sequence and to methods for its purification and use. The protein binds but does not degrade or cleave C3 and is implicated in *S. pneumoniae* virulence. The protein is recognized by antibodies produced by humans recovering from pneumococcal infection.

PbcA Binds C3 in ELISA



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

Intern. Application No
PCT/US 97/20586

A. CLASSIFICATION OF SUBJECT MATTER					
IPC 6 C12N15/31 C12N1/21 C07K14/315 C07K16/12 A61K39/09 A61K39/40 //((C12N1/21,C12R1:46))					
According to International Patent Classification (IPC) or to both national classification and IPC					
B. FIELDS SEARCHED					
Minimum documentation searched (classification system followed by classification symbols)					
IPC 6 C12N C07K A61K					
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched					
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)					
C. DOCUMENTS CONSIDERED TO BE RELEVANT					
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.			
P,X	WO 97 41151 A (UNIV ROCKEFELLER) 6 November 1997 see page 9, line 11 - line 19 see page 67, line 14 - line 25 see page 73, line 18 - page 74, line 8 SEQ ID no.24,25 see page 76, line 15 - page 78, line 13; claims 1-40 --- EP 0 622 081 A (UAB RESEARCH FOUNDATION) 2 November 1994 see the whole document --- WO 93 24000 A (YOTHER JANET) 9 December 1993 see the whole document --- -/-	1-68 1-68 1-68 -/-			
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.					
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed					
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family					
Date of the actual completion of the international search		Date of mailing of the international search report			
8 May 1998		02.06.98			
Name and mailing address of the ISA			Authorized officer		
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016			Hornig, H		

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/20586

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	ANONYMOUS: "A C3 - binding protein from <i>Streptococcus pneumoniae</i> ." 97TH GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY, MIAMI BEACH, FLORIDA, USA, MAY 4-8, 1997. ABSTRACTS OF THE GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY 97 (O). 1997. 110. ISSN: 1060-2011, XP002064458 Accession no. B-478	1-28, 33-47
P,X	C. ROSENOW ET AL.: "Contribution of novel choline-binding proteins to adherence, colonization and immunogenicity of <i>Streptococcus pneumoniae</i> " EMBL SEQUENCE DATABASE, 29 September 1997, HEIDELBERG, FRG, XP002064459 Accession no. AF019904; AC 030874;	1-28, 33-47
P,X	S. HAMMERSCHMIDT ET AL.: "SpsA, a novel pneumococcal surface protein with specific binding to immunoglobulin A and secretory components" EMBL SEQUENCE DATABASE, 14 October 1997, HEIDELBERG, FRG, XP002064460 Accession no. AJ002054	1-28, 33-47

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 97/20586

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 55-63 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/20586

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9741151	A 06-11-1997	AU 2818297	A	19-11-1997
EP 0622081	A 02-11-1994	AU 682018	B	18-09-1997
		AU 5769694	A	27-10-1994
		CA 2116261	A	21-10-1994
		FI 941695	A	21-10-1994
		JP 7126291	A	16-05-1995
		NO 941420	A	21-10-1994
		US 5679768	A	21-10-1997
		ZA 9401584	A	12-10-1994
WO 9324000	A 09-12-1993	AU 4400293	A	30-12-1993




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :	C12N 15/31, 1/21, C07K 14/315, 16/12, A61K 39/09, 39/40 // (C12N 1/21, C12R 1:46)	A3	(11) International Publication Number:	WO 98/21337
(21) International Application Number:	PCT/US97/20586		(43) International Publication Date:	22 May 1998 (22.05.98)
(22) International Filing Date:	12 November 1997 (12.11.97)			
(30) Priority Data:			(81) Designated States:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
60/029,444	12 November 1996 (12.11.96)	US		
60/038,086	18 February 1997 (18.02.97)	US		
60/059,368	19 September 1997 (19.09.97)	US		
60/062,473	16 October 1997 (16.10.97)	US		
(71) Applicant (for all designated States except US): REGENTS OF THE UNIVERSITY OF MINNESOTA [US/US]; Morrill Hall, 100 Church Street S.E., Minneapolis, MN 55455 (US).			(Published)	
(71)(72) Applicants and Inventors: HOSTETTER, Margaret, K. [US/US]; 1832 Kenwood Parkway, Minneapolis, MN 55405 (US). CHENG, Qi [CN/US]; 11240 48th Avenue North, Plymouth, MN 55442 (US). FINKEL, David, J. [US/US]; Apartment 3, 414 S.E. Erie Street, Minneapolis, MN 55414 (US). SMITH, Beverly [US/US]; 1973 Sheridan Avenue South, Minneapolis, MN 55405 (US).			With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(74) Agent: MCCORMACK, Myra, H.; Mueting, Raasch, Gebhardt & Schwappach, P.A., P.O. Box 581415, Minneapolis, MN 55458-1415 (US).			(88) Date of publication of the international search report:	23 July 1998 (23.07.98)

(54) Title: C3 BINDING PROTEIN OF *STREPTOCOCCUS PNEUMONIAE*

(57) Abstract

This invention relates to the identification of a human complement C3 binding protein from *Streptococcus pneumoniae* and to its sequence and to methods for its purification and use. The protein binds but does not degrade or cleave C3 and is implicated in *S. pneumoniae* virulence. The protein is recognized by antibodies produced by humans recovering from pneumococcal infection.

*PbcA Binds C3 in ELISA**Saturation of C3 Binding*

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

C3 BINDING PROTEIN OF *STREPTOCOCCUS PNEUMONIAE*

Field of the Invention

This invention relates to *Streptococcus pneumoniae* and in particular this invention relates to the identification of an *S. pneumoniae* protein that is implicated in *S. pneumoniae* virulence and is capable of binding the complement protein, C3.

Background of the Invention

This application is a continuation in part of a provisional application filed October 16, 1997 (U.S. Serial No. 60/062,473) entitled "C3 BINDING PROTEIN OF *S. PNEUMONIAE*." This application is also a continuation in part of a provisional application filed on September 19, 1997 (U.S. Serial No. 60/059,368), a provisional application filed on February 18, 1997 (U.S. Serial No. 60/038,086) and a provisional application filed on November 12, 1996 (U.S. Serial No. 60/029,444) all entitled "C3 BINDING PROTEIN OF *S. PNEUMONIAE*."

Respiratory infection with the bacterium *Streptococcus pneumoniae* (*S. pneumoniae*) leads to an estimated 500,000 cases of pneumonia and 47,000 deaths annually. Those persons at highest risk of bacteremic pneumococcal infection are infants under two years of age and the elderly. In these populations, *S. pneumoniae* is the leading cause of bacterial pneumonia and meningitis. Moreover, *S. pneumoniae* is the major bacterial cause of ear infections in children of all ages. Both children and the elderly share defects in the synthesis of protective antibodies to pneumococcal capsular polysaccharide after either bacterial colonization, local or systemic infection, or vaccination with purified polysaccharides. *S. pneumoniae* is the leading cause of invasive bacterial respiratory disease in both adults and children with HIV infection and produces hematogenous infection in these patients (Connor et al. *Current Topics in AIDS* 1987;1:185-209 and Janoff et al. *Ann. Intern. Med.* 1992;117(4):314-324).

Individuals who demonstrate the greatest risk for severe infection are not able to make antibodies to the current capsular polysaccharide vaccines. As a result, there are now four conjugate vaccines in clinical trial. Conjugate vaccines consist of pneumococcal capsular polysaccharides coupled to protein carriers or adjuvants in an attempt to boost the antibody response. However, there are other potential problems with conjugate vaccines currently in clinical trials. For example, pneumococcal serotypes that are most prevalent in the United States are different from the serotypes that are most common in places such as Israel, Western Europe, or Scandinavia. Therefore, vaccines that may be useful in one geographic locale may not be useful in another. The potential need to modify currently available capsular polysaccharide vaccines or to develop protein conjugates for capsular vaccines to suit geographic serotype variability entails prohibitive financial and technical complications. Thus, the search for immunogenic, surface-exposed proteins that are conserved worldwide among a variety of virulent serotypes is of prime importance to the prevention of pneumococcal infection and to the formulation of broadly protective pneumococcal vaccines. Moreover, the emergence of penicillin and cephalosporin-resistant pneumococci on a worldwide basis makes the need for effective vaccines even more exigent (Baquero et al. *J. Antimicrob. Chemother.* 20 1991;28S;31-8).

Several pneumococcal proteins have been proposed for conjugation to pneumococcal capsular polysaccharide or as single immunogens to stimulate immunity against *S. pneumoniae*. Surface proteins that are reported to be involved in adhesion of *S. pneumoniae* to epithelial cells of the respiratory tract include PsaA, PspC/CBP112, and IgA1 proteinase (Sampson et al. *Infect. Immun.* 1994;62:319-324, Sheffield et al. *Microb. Pathogen.* 1992; 13: 261-9, and Wani, et al. *Infect. Immun.* 1996; 64:3967-3974). Antibodies to these adhesins could inhibit binding of pneumococci to respiratory epithelial cells and thereby reduce colonization. Other cytosolic pneumococcal proteins such as pneumolysin, autolysin, neuraminidase, or hyaluronidase are proposed as vaccine antigens because antibodies could potentially block the toxic effects of

these proteins in patients infected with *S. pneumoniae*. However, these proteins are typically not located on the surface of *S. pneumoniae*, rather they are secreted or released from the bacterium as the cells lyse and die (Lee et al. *Vaccine* 1994; 12:875-8 and Berry et al. *Infect. Immun.* 1994; 62:1101-1108). While use of 5 these cytosolic proteins as immunogens might ameliorate late consequences of *S. pneumoniae* infection, antibodies to these proteins would neither promote pneumococcal death nor prevent pneumococcal colonization.

A prototypic surface protein that is being tested as a pneumococcal vaccine is the pneumococcal surface protein A (PspA). PspA is a 10 heterogeneous protein of about 70-140 kDa. The PspA structure includes an alpha helix at the amino terminus, a proline-rich sequence in the mid-portion of the protein, and terminates in a series of choline-binding repeats at the carboxy-terminus. Although much information regarding its structure is available, PspA is not structurally conserved among a variety of pneumococcal serotypes, and its 15 function is entirely unknown (Yother et al. *J. Bacteriol.* 1992;174:601-9 and Yother *J. Bacteriol.* 1994;176:2976-2985). Studies have confirmed the immunogenicity of PspA in animals (McDaniel et al. *Microb. Pathogen.* 1994; 17:323-337). Despite the immunogenicity of PspA, the heterogeneity of PspA, its existence in four structural groups (or clades), and its uncharacterized 20 function complicate its ability to be used as a vaccine antigen.

In patients who cannot make protective antibodies to the type-specific polysaccharide capsule, the third component of complement, C3, and the associated proteins of the alternative complement pathway constitute the first line of host defense against *S. pneumoniae* infection. Because complement 25 proteins cannot penetrate the rigid cell wall of *S. pneumoniae*, deposition of opsonic C3b on the pneumococcal surface is the principal mediator of pneumococcal clearance. Interactions of pneumococci with plasma C3 are known to occur during pneumococcal bacteremia, when the covalent binding of C3b, the opsonically active fragment of C3, initiates phagocytic recognition and 30 ingestion (Johnston et al. *J. Exp. Med* 1969;129:1275-1290, Hasin HE, *J. Immunol.* 1972; 109:26-31 and Hostetter et al. *J. Infect. Dis.* 1984; 150:653-61).

C3b deposits on the pneumococcal capsule, as well as on the cell wall. This method for controlling *S. pneumoniae* infection is fairly inefficient and could be beneficially amplified by the presence of antibodies to surface components of *S. pneumoniae*. There currently exists a strong need for methods and therapies to limit *S. pneumoniae* infection.

Summary of the Invention

The present invention relates to the identification and purification of an about 90 kDa to about 110 kDa (± 5 kDa) protein, as determined following electrophoresis on a 15% SDS-PAGE gel. The protein is named PbcA and is isolatable from *S. pneumoniae* strains that are capable of binding to human complement protein C3. The protein, PbcA, comprises an amino terminus containing region comprising SEQ ID NO:1 and is capable of binding but not cleaving or degrading the human complement protein C3. The protein also comprises a proline rich region and in one embodiment is a surface exposed protein of *S. pneumoniae*.

This invention also relates to the production of antibodies specifically recognizing PbcA. In one embodiment the antibodies are polyclonal and in another embodiment the antibodies are monoclonal. The antibodies can be produced by immunizing a mammal with all or a portion of PbcA. In one embodiment, the monoclonal antibodies are rodent derived.

In another aspect of this invention a method is provided for generating an immune response to *S. pneumoniae* *in vivo* comprising the steps of: administering a protein or an immunogenic fragment of a protein from *S. pneumoniae* to an animal wherein the amino terminus containing region of the protein comprises SEQ ID NO:1. In one embodiment, the protein is capable of binding but not cleaving or degrading the human complement protein C3. Preferably, the method further comprises detecting an immune response to *S. pneumoniae* in the mammal. Preferably, the immune response comprises the production of antibodies to *S. pneumoniae*. The animal can be a mouse, rat, chinchilla, a rabbit or a human and the method can further comprise the steps of

isolating antibody producing cells from the mammal and preparing monoclonal antibodies to the C3 binding protein.

In yet another aspect of the invention a method is disclosed for obtaining a purified C3 binding protein from *S. pneumoniae* comprising the steps 5 of: obtaining a protein sample from *S. pneumoniae*; precipitating the protein to form a precipitate; applying the precipitate to a Thiopropyl Sepharose 6B affinity chromatography column comprising methylamine-treated C3; and eluting the C3 binding protein from the column using an elution buffer comprising about 20% ethanol. In one aspect of this embodiment the invention relates to C3 binding 10 protein preparable by these methods.

This invention also relates to a C3 binding protein having the sequence of SEQ ID NO:6 and to isolated nucleic acid encoding a C3 binding protein and comprising the DNA sequence of SEQ ID NO:5 and to isolated nucleic acid having the DNA sequence of SEQ ID NO:4.

15 In another aspect of this invention, the invention relates to isolated nucleic acid encoding C3 binding protein of about 90 kDa to about 110 kDa (\pm 5 kDa), in one embodiment, and comprising nucleic acids 1-1500 of SEQ ID NO:5 and to an isolated nucleic acid sequence encoding the C3 binding protein wherein the protein exhibits C3 binding activity and wherein the protein 20 comprises at least 80% nucleic acid homology to nucleic acids 1-1500 of SEQ ID NO:5. Preferably, the nucleic acid homology is at least 95%.

The invention also relates to a C3 binding protein isolatable from *S. pneumoniae* having DNA that is hybridizable to a nucleic acid fragment of at least 500 bp from nucleic acids 1-1500 of SEQ ID NO: 5 under hybridization 25 conditions of about 6X SSC, 5X Denhardt's, 0.5% SDS, 100 μ g/ml denatured, fragment salmon sperm DNA overnight at 65°C and washed in 2X SSC, 0.1%SDS, one time at room temperature for about 10 mn, followed by one time at 65°C for about 15 mn and followed by at least one wash in 0.2 X SSC, 0.1% SDS at room temperature for about 3-5 minutes. Preferably this protein further 30 comprises at least 2 choline binding repeat and still more preferably the protein further comprises at least 2 choline binding repeats.

The invention also relates to peptide fragments of at least 15 bp from SEQ ID NO:5 and to insertion and deletion mutants that do not express PbcA.

In another aspect of this invention, the invention relates to PbcA proteins. In one embodiment the invention relates to an isolated protein comprising SEQ ID NO:1 and at least two choline binding repeats. Preferably the protein is isolated from *S. pneumoniae* and also preferably the protein binds human complement protein C3. In one version of this embodiment, the protein is a recombinant protein or a purified protein from *S. pneumoniae*. Preferably the protein has a molecular weight as determined on a 15% polyacrylamide gel of between about 90 kDa to about 110 kDa and preferably the protein comprises a proline rich region. Additionally the protein can comprise SEQ ID NO:2 or SEQ ID NO:3.

Alternatively, the protein of this invention can comprise SEQ ID NO:6 or the protein can be an isolated protein capable of binding to, but not cleaving or degrading, human complement C3 and wherein the protein comprises SEQ ID NO:1. Preferably the protein is isolated from *S. pneumoniae* and in one embodiment, the protein further comprises a proline rich region. The protein can further comprise SEQ ID NO:2. Preferably the protein has at least about 95% homology to a C3 binding protein from *S. pneumoniae* and also preferably, the protein has a molecular weight as determined on a 15% polyacrylamide gel of between about 90 kDa to about 110 kDa. In one aspect, the isolated protein is a recombinant protein and in another, the protein is isolated from *S. pneumoniae* bacteria.

In another embodiment of the proteins of this invention, the invention relates to a recombinant protein comprising SEQ ID NO:1, wherein the protein has a molecular weight as determined on a 15% polyacrylamide gel of between about 90 kDa to about 110 kDa. Preferably the protein binds human complement protein C3. The protein can further include a proline rich region and preferably the protein does not cleave or degrade human complement protein C3.

In another embodiment of the proteins of this invention, the protein comprises amino acids 1-410 of SEQ ID NO:6.

In yet another embodiment of the proteins of this invention, the invention relates to a protein that binds, but does not cleave or degrade, human complement protein C3, wherein nucleic acid encoding the protein hybridizes to SEQ ID NO:4 under hybridization conditions of 6X SSC, 5X Denhardt, 0.5% SDS, and 100 µg/ml fragmented and denatured salmon sperm DNA hybridized overnight at 65 °C and washed in 2X SSC, 0.1% SDS one time at room temperature for about 10 minutes followed by one time at, 65 °C for about 15 minutes followed by at least one wash in 0.2XSSC, 0.1% SDS at room temperature for at least 3-5 minutes. Preferably, the protein further comprises SEQ ID NO:1 and optionally, the protein can comprise SEQ ID NO:2 or SEQ ID NO:3. Preferably the protein is at least 15 amino acids in length. Preferably the protein comprises a proline rich region. In one aspect of this embodiment, the protein is a recombinant protein and in another, the protein is a synthetic peptide. In one aspect of this embodiment, the protein is a peptide of at least 15 amino acids from SEQ ID NO:6. The proteins can also be used to create antibody and the proteins of this embodiment can be used to generate antibody capable of specifically binding to the protein. In one embodiment, the antibody is a monoclonal antibody and in another the antibody is a polyclonal antibody. Preferably the monoclonal antibody is at least partially rodent-derived.

This invention also relates to nucleic acid encoding the proteins of this invention. In one embodiment, the nucleic acid of this invention encodes a protein comprising at least two choline binding domains and SEQ ID NO: 1. Preferably the protein encoded by the nucleic acid further comprising a proline rich region. Also preferably, the nucleic acid is isolated from an *S. pneumoniae* genome. Preferably, the nucleic acid is capable of hybridizing to SEQ ID NO:4 and in another embodiment, the protein encoded by the nucleic acid binds to human complement protein C3. In one aspect of this embodiment, the nucleic acid is positioned in a nucleic acid vector. Preferably the vector is an expression

vector and the expression vector directs expression of the protein by the nucleic acid.

In another embodiment of the nucleic acid of this invention, the invention relates to isolated nucleic acid encoding a protein comprising SEQ ID NO:1 and a proline rich region wherein the protein encoded by the nucleic acid binds but does not cleave or degrade human complement C3.

In yet another embodiment, the invention relates to isolated nucleic acid fragment encoding an about 90 kDa to about 110 kDa protein with C3 binding activity, wherein the nucleic acid fragment has at least 80% homology to at least 500 bp from nucleic acids 1-1500 of SEQ ID NO:5 and in another embodiment, the isolated nucleic acid fragment comprises base pairs 1-1500 of SEQ ID NO:5.

The invention also relates to a method for isolating a C3 binding protein from a bacterium comprising the steps of: obtaining a protein sample from a bacterium; applying the sample to a solid support comprising methylamine treated complement protein C3; washing the solid support; and removing a C3 binding protein from the solid support in a solution comprising alcohol wherein the C3 binding protein does not cleave or degrade C3.

Preferably the bacterium is *S. pneumoniae* and in another embodiment, the bacterium is *E. coli*. Preferably the solid support comprises an affinity column and preferably the alcohol is ethanol. In one embodiment, the solution comprising alcohol is a buffer comprising 20% ethanol. The invention also relates to C3 binding protein preparable by this method.

The invention also relates to a method for producing an immune response to *S. pneumoniae* comprising the steps of: administering a therapeutically effective amount of at least a portion of a protein to a mammal, wherein the protein binds but does not cleave or degrade human complement protein C3 and, wherein nucleic acid encoding the protein hybridizes to SEQ ID NO:4 under hybridization conditions of 6XSSC, 5X Denhardt, 0.5% SDS, and 100 µg/ml fragmented and denatured salmon sperm DNA, hybridized overnight at 65°C and washed in 2x SSC, 0.1% SDS one time at room temperature for

about 10 minutes followed by one time at 65°C for about 15 minutes followed by at least one wash in 0.2xSSC, 0.1% SDS at room temperature for at least 3-5 minutes; and detecting an immune response to the protein. In one embodiment, the protein is at least 15 amino acids in length and in another the protein is a
5 chimeric protein. In yet another embodiment, the protein comprises SEQ ID NO:1. In another embodiment, the protein has a molecular weight on a 15% polyacrylamide gel of between about 90 kDa to about 110 kDa.

The invention also relates to a method for reducing *S. pneumoniae* binding to C3 comprising the steps of: administering a
10 therapeutically effective amount of at least a portion of an antibody to a mammal, wherein the antibody specifically recognizes a C3 binding protein from *S. pneumoniae*, and wherein the C3 binding protein is a protein that binds, but does not cleave or degrade human complement protein C3. In one embodiment the antibody comprises at least one variable domain from a monoclonal
15 antibody. In another embodiment, the antibody is administered to the air passages of the mammal or intravenously.

In yet another aspect of this invention, the invention relates to a non-naturally occurring *S. pneumoniae* bacterium that does not express a detectable human complement C3 binding protein, wherein the C3 binding
20 protein comprises SEQ ID NO:1. In one embodiment, the bacterium is the product of an insertion into the gene encoding the C3 binding protein and in another, the bacterium is a product of a deletion in the gene encoding the C3 binding protein. In yet another embodiment, the bacterium is produced by homologous recombination of the gene encoding the C3 binding protein gene
25 with at least a portion of a non-native C3 binding protein gene and in one aspect of this embodiment, the gene encoding at least a portion of the non-native C3 binding protein comprises a mutation within the non-native gene.

Brief Description of the Figures

Fig. 1 is an amino acid alignment of the choline binding regions
30 of PbcA from *S. pneumoniae* strains CP1200, R6x and 23F (SEQ ID NOS:9, 10, and 11).

Fig. 2 is a graph illustrating PbcA binding to human C3 by ELISA.

Fig. 3 summarizes studies to assess the ability of antibody to PbcA to inhibit C3 binding. Figure 3a is a Western blot illustrating the specificity of the antibody preparation for PbcA from CP1200. Figure 3b is a graph illustrating the ability of antibody to PbcA to inhibit C3 binding by ELISA.

Fig. 4 illustrates an exemplary strategy for producing a *pbcA* insertion mutant.

Fig. 5a is a photograph of a Southern blot of DNA from transformed and nontransformed *S. pneumoniae* cells probed with a 1.5kb fragment of *pbcA*. Figure 5b is a photograph of a Southern blot probed with vector pVA891.

Figure 6 is a photograph of Western blot experiments demonstrating that the insertion-duplication mutants of this invention do not produce PbcA protein capable of binding C3 or antibody to PbcA.

Detailed Description of the Preferred Embodiments

The present invention provides a *S. pneumoniae* protein that binds C3. The protein is about 90 kDa to about 110 kDa (\pm about 5 kDa) in mass as observed following electrophoresis on a 15% SDS-PAGE gel and is referred to in this disclosure as "PbcA." PbcA was initially identified using the methods of Example 1. Supernatant proteins from exponentially growing cultures of *S. pneumoniae* were tested by Western blot for their ability to bind to purified human C3 following electrophoresis on a 15% SDS-PAGE gel. In the *S. pneumoniae* strain CP1200, both lysates and supernatants from exponentially growing cells produced a protein band, identified as PbcA, at approximately 90 kDa on 15% SDS-PAGE gels under non-reducing conditions. The protein bound methylamine-treated human C3 (produced as described by Hostetter MK, et al. *J. Inf. Dis.* 150:653-661, 1984), labeled with biotin. PbcA is present in lysates and supernatants from a variety of other *S. pneumoniae* strains. The size of PbcA

varies on a 15% SDS-PAGE gel in *S. pneumoniae* strains from about 90 kDa to about 110 kDa. All PbcA proteins identified thus far are capable of binding, but not cleaving or degrading, purified human complement protein C3. In some strains protein bands of smaller molecular weight are observed.

As will be recognized by those of skill in the art, there are a variety of methods for isolating an individual protein from bacterial supernatants. As one example, the *S. pneumoniae* C3 binding protein, PbcA, is isolated using the methods of Example 2. PbcA, can be purified from other secreted pneumococcal proteins by affinity chromatography. Secreted proteins can be precipitated in a final concentration of 10% trichloroacetic acid (TCA) at 4°C overnight according to Example 2. Resuspended proteins from the TCA precipitate are subjected to affinity column chromatography using methylamine-treated human C3 (*supra*). Elution of the PbcA protein from the affinity column has proven to be difficult. Surprisingly, the PbcA protein from the column can be eluted using an elution buffer comprising an alcohol, preferably ethanol and more preferably about 20% ethanol in the Tris-HCl/NaCl wash buffer. In view of this disclosure, now that PbcA has been identified, those skilled in the art will recognize that other methods could be used to identify, isolate and purify the protein from a variety of C3-binding *S. pneumoniae* without undue experimentation.

Multiple eluates can be pooled to obtain sufficient sample for further analysis. As one example, a sample can be electrophoresed on an SDS-PAGE gel and transferred to nitrocellulose. The protein can be subjected to amino terminal analysis and tryptic digestion for internal peptide sequencing.

The following sequences were obtained from the tryptic digest analysis:

- A peptide positioned near the amino terminus:
TENEGSTQAAATSSNMAKTEH (SEQ ID NO:1)
- And internal regions:
EKPAEQQPQAPATQP (SEQ ID NO:2)
SSDSSVGEETLPSSSLK (SEQ ID NO:3)

SEQ ID NO:2 is proline rich and has at least a 75% homology with the *S. pneumoniae* protein PspA over 13 amino acids. Although the proline rich region of PspA aligned with SEQ ID NO:2, neither SEQ ID NO:1 nor SEQ ID NO:3 had any substantial homology to any proteins or peptides previously published in the GenBank database (less than 35% homology). The term "proline rich" as used herein refers to a protein having a stretch of amino acids having at least 5 proline amino acids over a total of about 15 amino acids.

These sequences were confirmed in *S. pneumoniae* strain CP1200 following isolation of the gene and sequencing to obtain the nucleic acid sequence encoding PbcA. In one embodiment of this invention, PbcA is an about 90 kDa to about 110 kDa (\pm 5 kDa, meaning about 85 kDa to about 115 kDa) when *S. pneumoniae* proteins are separated on a 15% SDS-PAGE gel, and in another embodiment, the protein further includes SEQ ID NO:2 and SEQ ID NO:3.

Oligonucleotides corresponding in whole or in part to SEQ ID NOS: 1-3 are useful for identifying and isolating the nucleic acid encoding PbcA (the gene encoding PbcA is termed *pbcA*) and for isolating the *pbcA* and PbcA from a variety of *S. pneumoniae* strains. For example, oligonucleotides corresponding in whole or in part from SEQ ID NOS 1-3 can be used to amplify sequences from genomic DNA isolated from *S. pneumoniae* using standard polymerase chain reaction technology. The amplified sequences can then be directly used as probes or the amplified sequences can be incorporated into a vector for plasmid amplification in a suitable host such as a bacteria or virus and then isolated for sequencing, cloning and for use as probes to detect DNA from libraries of *S. pneumoniae*. The DNA isolated from these procedures is useful in sequencing reactions to obtain the nucleic acid sequence encoding PbcA and to produce vectors, such as expression vectors encoding PbcA as well as for producing recombinant protein. Example 5 provides a preferred method for isolating nucleic acid encoding PbcA.

PbcA can be expressed as a recombinant protein or isolated from *S. pneumoniae* lysates. The *S. pneumoniae* C3 binding protein, PbcA, binds C3

without cleaving or degrading the C3 molecule. A number of bacterial proteins have been reported to bind and to cleave C3 or other complement proteins. For example, a 140 kDa C5a peptidase from group A streptococci cleaves a His₆₇-Lys₆₈ bond at the carboxy terminus of C5a, thereby abolishing the chemoattractant capabilities of the molecule. An enzyme related to the C5a peptidase is also found in group B streptococci (Cleary et al. *Infect. Immun.* 1992; 60:4239-4244 and Bohnsack et al. *Biochim. et Biophys. Acta* 1991; 1079:222-228). Production of an elastase-like enzyme, as can be seen with 24-hour culture supernatants from *Pseudomonas aeruginosa* (Suter et al. *J. Infect. Dis.* 1984; 149:523-31), cleaves C3 into characteristic fragments of 66 kDa and 100 kDa from the C3 α -chain. Like the elastase-like enzyme from *P. aeruginosa*, a 56 kDa neutral cysteine proteinase from *Entamoeba histolytica* cleaves C3a between residues Ser₇₈/Asn₇₉, yielding a defined C3 cleavage fragment of 105 kDa (Reed, et al. *J. Immunol.* 1989; 143:189-95).

C3-cleaving proteinases have been isolated from the membranes of some mammalian cells, including human erythrocytes (p57), neutrophils, and melanoma cells resistant to complement-mediated killing. These proteins are typically serine proteases which yield defined cleavage fragments. For example, p57 cleaves both the α - and β -chains of C3, while the melanoma proteinase cleaves only the α' -chain of C3b, generating a fragment of 35 kDa (Charriaut-Marlangue et al. *Biochem. Biophys. Res. Commun.* 1986; 140:1113-1120 and Ollert et al. *J. Immunol.* 1990; 144:3862-7).

In contrast to these studies, C3 cleavage and/or degradation was not observed with PbcA. PbcA binds C3 without the production of defined cleavage fragments and without evidence of degradation of C3. Although there are microbial precedents for binding and cleaving of complement proteins, there is no previously reported microbial protein that binds C3 non-covalently without degrading or cleaving the molecule. The interaction of C3 and other complement components with proteins from group A and B streptococci, *P. aeruginosa*, and amoebae appears to be quite distinct from what has been observed with *S. pneumoniae*.

Table 1 (SEQ ID NO:4) provides a nucleic acid sequence encompassing the open reading frame encoding a 90 kDa PbcA protein from *S. pneumoniae* strain CP1200. Untranslated 5' and 3' regions are also included in SEQ ID NO:4. The open reading frame encoding PbcA begins at nucleotide 383 and ends with nucleotide 2074. Table 2 is a map providing the amino acids (SEQ ID NO: 6) encoded by the nucleic acids of the major open reading frame from SEQ ID NO:4 (provided in Table 2 as SEQ ID NO:5). The protein predicted from SEQ ID NO:4 contains an amino terminus containing segment with C3 binding activity (upstream from the choline binding repeat region) and a series of choline binding repeats (beginning in SEQ ID NO:5 at about nucleic acid position 1501).

Primers were selected from SEQ ID NO:4 to span the choline binding repeats to assess choline binding repeat variability between strains. The primers used were:

15 5' GCACAACCATCTACTCCA 3' (SEQ ID NO: 7), and
 5' GTACAGGAATTCACTTAACTA 3' (SEQ ID NO:8)

Amplification reactions were performed using DNA from three different *S. pneumoniae* strains: CP1200, R6x and virulent strain 23F (obtained from Dr. Steve Pelton, Boston City Hospital, Boston, MA and identified as isolate "freezer #365"). The results of the amplification studies indicated that the number of choline binding repeats varied depending on the *S. pneumoniae* strain. For example, strain CP1200 contained about 4 repeats while 23F contained about 8 repeats and R6X contained at least about 10 choline binding repeats using the Yother et al. model for choline binding repeat regions (see *infra*). All 25 *S. pneumoniae* strains studied thus far have at least two choline binding repeats. Therefore, in another embodiment of this invention, PbcA is a C3-binding protein from *S. pneumoniae* including SEQ ID NO:1 and at least 2 choline binding repeats.

Choline binding domains are known in the art and a number of 30 references discuss the characteristics of a variety choline binding domains (see, for example, Du Clos et al. *J. Biol. Chem.* 266(4):2167-2171, 1991; Liu et al. *J.*

Biol. Chem. 266(22):14813-14821, 1991; Agrawal et al. *J. Biol. Chem.* 267(35):25352-25358, 1992; and *Nature Structural Biology* 3(4):346-354, 1994). A choline-binding repeat sequence has been identified in *S. pneumoniae* protein PspA as TGWKQENGMWYFYNTDGSMA (SEQ ID NO:12) (see
5 Yother, J. and White, JM, *J. Bacteriology* 176:2976-2985, 1994) Choline binding repeats are associated with membrane binding proteins. Without intending to limit this invention, the strains studied thus far indicate that the virulent strains appear to have more choline binding repeats on average than nonvirulent strains. At the very least it appears that *S. pneumoniae* strains show
10 considerable variability in the choline binding repeat region.

These results are consistent with electrophoretic studies assessing variability in the size of PbcA proteins obtained from a number of *S. pneumoniae* strains. Proteins isolated according to the methods of this invention, when separated by SDS-PAGE, demonstrate some size variability (See Fig. 6) from
15 about 90 kDa to about 110 kDa (\pm 5 kDa). This variability can be attributed, at least in part, to the variability in length of the choline binding repeat region. The proteins of this invention also include a series of peptides at the carboxy terminus of the choline binding repeat region.

Fig. 1 provides a comparison of the amino acid sequence from a
20 region containing the choline binding repeat region from PbcA for three different *S. pneumoniae* strains: CP1200, R6x and 23F(BD23). The amino acids in the boxes represent variations in the 23F (virulent strain BD23) choline binding domain repeat region (SEQ ID NOS: 9, 10, and 11).

One example of a fragment containing nucleic acid encoding
25 PbcA protein is provided in SEQ ID NO:4. The nucleic acid sequence encoding PbcA in strain CPI200 is provided as SEQ ID NO:5 (see Table 2). In another aspect of this invention, a protein of this invention has the amino acid sequence of SEQ ID NO:6. In one embodiment, a protein of this invention includes amino acids 1-410 of SEQ ID NO:6. In addition, variability between strains has been
30 identified at the amino acid and nucleic acid level. For example, the amino terminus contains some variability and SEQ ID NO:1 may lack the first

threonine residue. In general, PbcA proteins include C3 binding proteins from *S. pneumoniae* that preferably have at least 80% nucleic acid homology within the DNA of the amino terminus-containing region (the region amino-terminal to the choline binding repeats) to SEQ ID NO:5. More preferably, the PbcA proteins
5 have at least 95% homology to the amino terminus-containing region of PbcA and still more preferably the PbcA protein includes SEQ ID NO:1. In another embodiment the PbcA proteins additionally include SEQ ID NO:2 or SEQ ID NO:3.

In one example, the nucleic acid encoding PbcA can be obtained
10 from a variety of *S. pneumoniae* strains. A *S. pneumoniae* genomic library can be prepared using *S. pneumoniae* genomic DNA and in a preferred example, an *S. pneumoniae* genomic library was prepared using the CP1200 strain. Custom libraries can be obtained using a variety of standard methods for library construction. In these studies genomic DNA from *S. pneumoniae* was given to a
15 commercial custom library supplier (Stratagene, LaJolla, CA). In one example, *S. pneumoniae* CP1200 strain genomic DNA was used to prepare the library (Example 5) The results of these studies identified a cloned nucleic acid fragment encoding PbcA. This fragment is useful for identifying PbcA encoding nucleic acid in other *S. pneumoniae* strains and the nucleic acid can be
20 incorporated into vectors including expression vectors, for example to produce recombinant protein using methods such as those described by Sambrook et al. (cited below).

PbcA is preferably encoded by nucleic acid that is capable of hybridizing to at least 500 bp from the amino terminus region of SEQ ID NO: 5
25 under hybridization conditions of about 6X SSC, 5X Denhardt's, 0.5% SDS, 100 µg/ml denatured, fragmented salmon sperm DNA hybridized overnight at 65°C and washed in 2X SSC, 0.1%SDS, one time at room temperature for about 10 mn, followed by one time at 65°C for about 15 mn and followed by at least one wash in 0.2 X SSC, 0.1% SDS at room temperature for about 3-5 minutes. The
30 protein of this invention preferably includes at least two and preferably at least three choline binding repeats.

This invention also relates to nucleic acid fragments of at least 20 bp from SEQ ID NO:5 and to isolated nucleic acid fragments of at least 100 base pairs that hybridize to the *S. pneumoniae* genome or to SEQ ID NO:5 under the hybridization conditions of about 6X SSC, 5X Denhardt's, 0.5% SDS, 100 5 µg/ml denatured, fragment salmon sperm DNA hybridized overnight at 65°C and washed in 2X SSC, 0.1%SDS, one time at room temperature for about 10 min., followed by one wash at 65°C for about 15 min and followed by at least one wash in 0.2 X SSC, 0.1% SDS at room temperature for about 3-5 minutes. Preferably the nucleic acid fragments of at least 100 base pairs are part of a 10 nucleic acid sequence that encodes a C3 binding protein that is at about 90 kDa to about 110 kDa. Preferably the nucleic acid fragment encodes a protein having at least two choline binding repeats.

As demonstrated in Example 3, the immunogenicity of PbcA can be studied by testing for the presence of antibodies to PbcA in acute and 15 convalescent sera from patients with culture-proven pneumococcal infection. *S. pneumoniae* proteins can be separated by SDS-PAGE electrophoresis, transferred to nitrocellulose, and incubated with acute or convalescent serum (standard Western blot procedure). Results to detect the presence of antibodies to PbcA in human sera indicated that acute serum did not contain antibodies to 20 any pneumococcal proteins released into the supernatant but that convalescent serum contained antibodies that recognized a band on an acrylamide gel with a molecular weight of PbcA.

PbcA, or fragments of PbcA, can be used to produce antibodies specific to PbcA. The term "specific" is used to mean that when the antibodies 25 to PbcA or fragments thereof are used in Western blots containing PbcA or a PbcA fragment or peptide under standard Western Blot assay conditions, the antibodies recognize only PbcA or its degradation or truncated products. Purified PbcA or fragments, preferably of at least about 15 amino acids in length, can be used to inject laboratory animals for the production of polyclonal and 30 monoclonal antibodies to PbcA. Those skilled in the art will recognize that the methods for producing polyclonal antibodies and for producing monoclonal

- antibodies are known in the art and include the methods disclosed by Harlow et al. (cited below). Purified antibodies can be generated using the isolated protein of this invention, or fragments thereof, without undue experimentation. The antibodies are useful in *in vitro* assays to test for the presence or absence of
- 5 PbcA protein and to test for the ability of the antibodies to block C3 binding as well as in *in vivo* assays to test for the ability of the antibodies to provide passive protection against pneumococcal infection, whether local or systemic. Antibody fragments and chimeric antibodies can be used and the antibodies include at least one variable domain from an antibody specifically recognizing PbcA.
- 10 Moreover, purified proteins, peptides and polypeptides from PbcA can be injected into animals, and later humans, to produce an antibody response to *S. pneumoniae*. As used herein, the terms proteins, peptides and polypeptides are used interchangeably. Therefore, for purposes of this application and as used in the claims, a protein refers to proteins, protein fragments, peptides and polypeptides. Methods for introducing the protein, peptide or polypeptide fragment of PbcA to a mammal with an appropriate adjuvant, if necessary, are known in the art. Moreover, all or a portion of PbcA can be produced as an isolated protein or as a recombinant protein. Recombinant proteins can include all or a part of PbcA or can be formed as a chimeric protein.
- 15
- 15 As used herein, the term "chimeric protein" refers to a recombinant protein including all or at least 15 amino acids of PbcA and amino acid sequence from at least one other protein positioned amino to, carboxy to, or on either side of the PbcA-derived amino acid.. The 15 amino acids of PbcA of the chimeric protein are preferably unique to *S. pneumoniae*-derived proteins. Since patients with
- 20 cleared *S. pneumoniae* infection have convalescent antibodies recognizing PbcA, it is known that the immune system can mount an immune response that includes the production of antibodies to PbcA. Ultimately, PbcA can be used as an immunogen for a pneumococcal vaccine. Further, based on the findings of these studies, antibody produced from the isolated protein, PbcA, can be used in
- 25
- 25 Western Blot analyses to determine whether or not a particular *S. pneumoniae*
- 30

strain's virulence or avirulence has been associated with the presence or absence of PbcA.

- As demonstrated in Example 4, PbcA is implicated in pneumococcal virulence (see Example 4). In this example an avirulent 23F 5 pneumococcal isolate was inoculated into the ears of chinchillas. Virulent pneumococcal isolates typically cause otitis media and the influx of leukocytes after injection at concentrations as low as 1×10^2 colony forming units (cfu). In contrast, the avirulent 23F strain was inoculated at concentrations of up to about 1×10^7 cells and even at that level was unable to cause otitis media or 10 inflammation (Giebink et al. *J. Infect. Dis.* 1993; 167:347-355). As discussed in Example 4, studies disclosed here indicate that the avirulent strain reported by Giebink lacked detectable PbcA protein by Western blot. To further study the implications of PbcA on virulence, an insertion/duplication mutation of PbcA was prepared for further study (see Example 8).
- 15 The present invention provides a detailed method of purification of PbcA and studies indicat that PbcA is: (a) immunogenic in man; (b) conserved within the mass range of about 90 kDa to about 110 kDa (as observed on a 15% SDS-PAGE gel) among a variety of pneumococcal serotypes (that is, PbcA has been identified in a variety of serotypes); and (c) absent in an avirulent 23F 20 strain that is incapable of causing otitis media in a chinchilla model.

To demonstrate that PbcA can be detected in an ELISA assay, PbcA coated wells of an ELISA plate were incubated with antibody prepared to purified PbcA from *S. pneumoniae* strain CP1200.

- 25 To demonstrate the ability of PbcA to bind human C3, purified PbcA from CP1200 was used to coat ELISA plates and the coated protein was incubated with methylamine-treated human C3. The binding of methylamine-treated human C3 was assessed using antibody to human C3 conjugated with horeseradish peroxidase (See Example 7). Figure 2 is a graph illustrating the ability of PbcA to bind increasing concentrations of human C3. Specific 30 antibody to PbcA blocked the binding of purified human C3 to PbcA in a dose-dependent fashion. These experiments are detailed in Example 7 and in Figure

3. The Western blot (Figure 3a) demonstrates that the IgG fraction of antibody to PbcA blocked the binding of human C3 to PbcA immobilized on nitrocellulose. The graph (Figure 3b) demonstrates that affinity-purified antibody to PbcA blocked the binding of human C3 to PbcA immobilized on 5 ELISA plates.

A PbcA insertion construct was prepared to interrupt a *pbcA* gene in CP1200 and R6x. An exemplary protocol is provided in Example 8 for producing an exemplary construct suitable for homologous recombination. Figure 4 illustrates a preferred method for preparing an insertion construct to 10 inactivate the *pbcA* gene in *S. pneumoniae*. In these methods, a gene encoding PbcA (a non-native C3 binding protein) is introduced into a cell containing PbcA. The non-native C3 binding protein is homologous to the PbcA in the cell to facilitate homologous recombination and the production of insertional mutations. The presence of the insertion mutant was confirmed by Southern blot 15 for a number of mutated R6X and CP1200 strains following transformation of these strains with the mutating construct pBV004 (see Figure 4). Mutated strains were tested by Southern blot using a 1.5 kb fragment of *pbcA* or vector pVA891 probes. Wild type strain BD23 was not transformed in these studies. Results of the Southern blot experiments are provided in Figure 5.

20 The insertion mutants were tested for their ability to produce PbcA protein using either human C3 or antibody to PbcA (Figure 4). Results indicated that no protein approximating the size of PbcA was detectable in supernatants from the *S. pneumoniae* strains tested on Western blot. Further, neither C3 nor antibody to PbcA bound on the Western blots. Therefore, the 25 mutants are useful to assess functional aspects of PbcA and to serve as a negative control for a variety of PbcA-related experiments.

As noted above, PbcA binds noncovalently to C3. *S. pneumoniae* is generally cleared from the body by the covalent opsonic deposition of C3b on the pneumococcal capsule or cell wall, followed by phagocytosis via C3 receptors or Fc receptors on neutrophils or monocytes/macrophages. 30 Nonopsonic (i.e. non-covalent) binding of C3 by pneumococcal surface proteins,

such as PbcA, suggests a mechanism whereby pneumococci can evade opsonization. Without intending to limit the scope of this invention, it is possible that PbcA protein from *S. pneumoniae* could bind C3 *in vivo* and reduce the amount of C3 available for opsonization. Antibodies to PbcA could block 5 the C3-binding effect and restore the opsonic activity of C3 in plasma.

- PbcA can be used in *in vitro* assays to assess the effect of PbcA on cells. For example, in Example 6, purified PbcA was added to cell cultures to study the role of PbcA in *S. pneumoniae* pathogenesis. PbcA can be tested for its toxicity on a variety of cells as well as tested in *in vivo* models for toxicity.
- 10 The results of Example 6 indicated that PbcA, as an intact protein, was toxic to pulmonary epithelial cells and that it stimulated production of the cytokine IL-8 from the epithelial cells. IL-8 is a cytokine that, among other things, stimulates neutrophil migration. Increased concentrations of neutrophils are observed in the lungs of patients with significant *S. pneumoniae* infection in the lung
- 15 passageways. Neutrophils and other white blood cells produce a variety of degradatory enzymes that damage lung tissue in *S. pneumoniae* infection and, based on these studies, lung damage can be the result of enzymatic release from white blood cells, PbcA, or both.

S. pneumoniae can colonize the nasopharynx, infect the lung and 20 ultimately disseminate to the blood, meninges or other sites. Antibody to PbcA can be tested for its ability to reduce the toxicity of the organism to the lung tissue and antibody to PbcA can be tested for its ability to prevent PbcA binding to C3 and to permit C3 to remain available during *S. pneumoniae* infection. Similarly, peptides and polypeptides to PbcA can be administered to mammals 25 and used in studies to assess the ability of the immune system to produce antibody to limit *S. pneumoniae* infection.

Animal models to study *S. pneumoniae* pathogenesis are known in the art. These include, but are not limited to, the chinchilla model for otitis media, the infant rat model for *S. pneumoniae* colonization and bacteremia, the 30 mouse model for colonization, bacteremia and meningeal infection and a rabbit model for studying infection in the meninges. Those of ordinary skill in the art

will recognize that antibodies to PbcA (whether exogenously administered or the product of immunization with all or a part of PbcA) can be tested in these models for their ability to limit or inhibit *S. pneumoniae* infection. Exogenously (i.e., passively) administered antibody can be given through a variety of 5 parenteral routes including, but not limited to, intravenous administration or administration to the air passages of a mammal such as a mouse, chinchilla, rat, rabbit or human.

All references and publications cited herein are expressly incorporated by reference into this disclosure. Particular embodiments of this 10 invention will be discussed in detail and reference has been made to possible variations within the scope of this invention. There are a variety of alternative techniques and procedures available to those of skill in the art which would similarly permit one to successfully perform the intended invention.

15

Example 1
Identification of PbcA from *S. pneumoniae*

10 ml of *S. pneumoniae* strain CP1200 (obtained from D.A. Morrison, University of Illinois, Champagne-Urbana, Illinois and described in 20 Havarstein LF, et al. *Proc. Natl. Acad. Sci. (USA)* 1995;92:11140-11144) was grown to exponential phase ($O.D._{620} \approx 0.3$) in Todd Hewitt broth (Fisher, Pittsburgh, PA) or in a synthetic medium ($O.D._{620} \approx 0.15$, media described by Sicard, A.M. *Genetics* 1964 59:31-44). Pneumococcal cells were pelleted and the supernatant was removed and precipitated with a final concentration of 10% 25 trichloroacetic acid (TCA) at 4°C overnight and samples were electrophoresed on 15% sodium dodecyl sulfate polyacrylamide gels (SDS-PAGE) under non-reducing conditions. Pneumococcal proteins separated by electrophoresis were then transferred to nitrocellulose for Western blotting. After blocking of the Western blot according to standard protocols (Harlow , et al. *Antibodies; A 30 Laboratory manual*. Cold Spring Harbor, NY; Cold Spring harbor Laboratory Press, 1988; 471-510) the blot was incubated with 10 mls of binding buffer containing about 2 µg/ml of purified human C3 (Hostetter et al. *J. Infect. Dis.*

1994; 150:653-661), labeled with biotin. The blot was washed and incubated with a 1:20,000 dilution of HRP-avidin for 60 minutes at room temperature and developed using the Supersignal™ system (Pierce, Rockford, IL) according to manufacturer's instructions. Purified human C3 bound to a band of about 90
5 kDa under non-reducing and reducing conditions on a 15% SDS-PAGE gel. Similarly, a protein of about 90 kDa was detected when cells were lysed in 5% SDS at room temperature for 30 minutes and following centrifugation, the supernatant was separated on a 15% SDS-PAGE gel.

Experiments were repeated with the substitution of 2 µg/ml
10 biotinylated C3 after treatment with methylamine (using the methods disclosed in Hostetter, et al. *J. Infect. Dis.* 1984; 150:653-661) to demonstrate that the 90 kDa protein in pneumococcal supernatants and lysates could bind non-opsonic forms of C3. Results again indicated that a 90 kDa protein was recognized by C3. A variety of pneumococcal strains were also tested. C3 bound to PbcA
15 identified in Western blots using supernatants from a variety of virulent pneumococcal strains (serotypes 1,3 [4 strains], 4, 14, 19F)

Example 2
Purification of PbcA

20 *S. pneumoniae* CP1200 was grown to mid-exponential phase in 4 liters of Todd Hewitt broth at 37°C. Pneumococcal cells were pelleted by centrifugation at 10,000 x g for 10 minutes. Proteins in the supernatant were precipitated with a final concentration of 10% trichloroacetic acid at 4 °C overnight. The
25 precipitate was resuspended in 40 mls of 100 mM Tris and the final pH adjusted to 7.0. The resuspended proteins were chromatographed on a 1.2 ml column of Thiopropyl Separaose 6B coupled by a disulfide bond to 4 mg methylamine treated human C3. The column was then washed with 40 ml of 100 mM Tris-HCl, pH 7.0 containing 0.5 M NaCl. PbcA was eluted from the column with
30 20% ethanol in the Tris-HCl/NaCl wash buffer. 1 ml. fractions were collected and analyzed by SDS-PAGE and C3 binding assay. A protein of about 90 kDa

to about 110 kDa (+/- 5 kDa) eluted from the C3 affinity column in fractions 2-10.

Multiple eluates from sequential purifications of PbcA from strain 1200 were pooled by precipitation with 90% ethanol to obtain sufficient sample for sequencing and further protein studies. Approximately 80 picomoles of the 5 protein were subjected to amino terminal analysis and tryptic digestion for internal peptide sequencing at the Harvard Microchemical Facility (Cambridge, MA).

**Example 3
Immunogenicity of PbcA**

10

Immunogenicity of PbcA was assessed by growing 10 ml of *S. pneumoniae* strain CP1200 to exponential phase in Todd Hewitt broth, pelleting the cells, and precipitating proteins from the supernatant with 10% TCA 15 overnight at 4°C. The next day, supernatant proteins were electrophoresed on 15% SDS-PAGE, transferred to nitrocellulose, blocked with skim milk in a standard protocol (Harlow, et al. *supra*) and incubated with a 1:10,000 dilution of acute or convalescent serum from a patient infected with *S. pneumoniae* (Dr. E. Janoff, Minneapolis VA Hospital, Minneapolis, MN). The blot was washed 20 according to methods disclosed in Harlow et al. and incubated with a 1:50,000 dilution of commercially purchased goat anti-human IgG conjugated to horseradish peroxidase (Chemicon, Temecula, CA). The blot was washed and developed with the Supersignal™ system according to manufacturer's instructions.

25

Western blots from these studies demonstrated that acute serum did not contain IgG antibodies to any pneumococcal proteins released into the supernatant but that convalescent serum contained IgG antibodies that recognized a protein of 90 kDa, consistent with the mass of PbcA. These experiments confirmed that PbcA elicited an immune response in humans 30 recovering from *S. pneumoniae* infection and indicated that PbcA is recognized by the human immune system.

Example 4
PbcA is implicated in *S. pneumoniae* virulence

Virulent pneumococcal isolates typically cause otitis media and
5 influx of leukocytes after inoculation in concentrations as low as 1×10^2
(Giebink et al. *J. Infect. Dis.* 1993; 167:347-355). Giebink et al. reported that an
avirulent serotype, type 23F, was inoculated into the ears of chinchillas and that
inoculum at concentrations of less than about 1×10^7 cells was unable to cause
otitis media or inflammation.

10 Both the type 23F avirulent strain (GD 23, *supra*) and a type 23F
virulent strain (BD23, Dr. Steve Pelton, Boston City Hospital, Boston, MA)
were grown to mid-exponential phase in Todd Hewitt broth, the cells were
pelleted, and supernatant proteins were precipitated in a final TCA concentration
of 10% overnight at 4°C. The following day, the precipitate was resuspended in
15 about 1 ml Tris, neutralized to pH 7.0, electrophoresed on 15% SDS-PAGE and
then transferred to nitrocellulose. Incubation of the nitrocellulose membrane
with 2 µg/ml of biotinylated, methylamine-treated C3 in binding buffer and
development of the Western blot with avidin conjugated to horseradish
peroxidase detected a PbcA band from a 15% SDS-PAGE gel in both cell lysates
20 and supernatants from the virulent type 23F, but PbcA was completely absent in
cell lysates and supernatants from the avirulent type 23F. In place of PbcA, a
smaller band of 33 kDa was identified. This band may represent a degradation
product or a truncated version of PbcA.

25

Example 5
Isolation of nucleic acid encoding PbcA

Degenerate oligonucleotides were obtained from a commercial
supplier based on the sequence of SEQ ID NO:1 and SEQ ID NO:2. The
30 oligonucleotides were used to amplify a 1500 bp sequence from CP1200
genomic DNA as template using standard polymerase chain reaction technology.
Template, primers, and buffer were added for one 5-minute cycle at 94°C. Then
dNTP's and Taq polymerase were added for 30 cycles, as follows: Double

stranded DNA was denatured for 1 min at 94°C, annealed for 1 min at 50°C, and extended for 2 min at 72°C. Final extension was completed in one 8-minute cycle at 72°C. The 1500 bp sequence was random primer labeled using a commercial kit and the sequence was used to screen the CP1200 genomic DNA library prepared under our direction by Stratagene (LaJolla, CA). Hybridization was performed under at least moderate stringency conditions and a variety of hybridization methods are provided in Sambrook et al. (*Molecular Cloning, A Laboratory Manual*, 1989 Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY). Exemplary hybridization conditions used were 65°C hybridization in 6X SSC (1M NaCl) using 5X Denhardt's, 20 mM sodium phosphate, 0.5% SDS and 100 µg/ml denatured sonicated salmon sperm DNA.

Three clones were identified that hybridized to the 1500 bp genomic DNA fragment; two overlapping clones of 4.3 and 5.3 kb, respectively and a third clone of 2.5 kb. Restriction mapping and hybridization studies suggested that the 5.3 kb clone contained an open reading frame encompassing the oligonucleotides from SEQ ID NO:1 and SEQ ID NO:2. A 3.2 kb fragment remaining after HindIII digestion and religation of the 5.3 kb clone is sequenced.

Example 6
20 **Stimulation of IL-8 Production from Pulmonary Epithelial Cells
 in Response to PbcA**

Monolayers of type II pulmonary epithelial cells (A549, American Type Culture Collection (ATCC), Rockville, MD) were incubated for 25 4 hours in culture supernatant (at least about 15µl supernatant diluted in 1 ml. serum free media (50% Hams F12/50% PBS) from exponentially growing *S. pneumoniae* (Pn) laboratory strain (CP1200, *supra*) or clinical isolates grown in Todd Hewitt broth (*supra*). Incubation of the epithelial cell monolayer in the culture supernatant induced the release of about 1169 pg/ml IL-8 while 30 incubation in media alone without culture supernatant and incubation in pneumococcal growth medium alone without culture supernatant was significantly less (p < 0.0001, see table below).

Supernatants from a virulent *S. pneumoniae* clinical isolate, 23F, were also effective at stimulating IL-8 production from pulmonary epithelial cells (about 1,495 pg/ml IL-8). Supernatants from a 23F strain that did not produce otitis media in an animal model did not induce IL-8 release *in vitro*.

5 Increasing the time for which CP 1200 supernatants were incubated with the epithelial monolayer from 4 to 24 hours resulted in an increase in IL-8 production to approximately two times the level of IL-8 obtained after a 4 hour incubation.

SDS-PAGE analysis of proteins in CP1200 *S. pneumoniae* 10 supernatants indicated that there a variety of proteins in the supernatants including five discrete bands correlating to identifiable proteins from *S. pneumoniae* that had sizes of about 180 kDa, 90 kDa, 57 kDa 42 kDa and 24 kDa. All five proteins were present in supernatants from the virulent 23F strain during exponential growth, but a band of about 90 kDa to about 110 kDa was 15 absent in supernatants from the avirulent 23F strain.

In identical assays, about 150-200 ng of affinity purified PbcA protein elicited at least about 1200 pg/ml IL-8 from pulmonary epithelial cells. This level was similar to that elicited using supernatants from CP1200 and virulent 23F strains after a 4-hour incubation. Thus, not only is PbcA potent in 20 eliciting IL-8 from pulmonary epithelial cells.

The combined results from 11 separate assays for IL-8 production are provided below:

	Stimulus	IL-8 Release (pg/ml) mean ± S.E.
25	Medium alone	580 ± 40
	Pneumo supt. Avir 23F(GD23)	471 ± 72
	Pneumo supt. Vir23F(BD23)	1,138 ± 83
	Pneumo supt. CP1200	1,169 ± 121
30	200 ng PbcA(CP1200)	1,679 ± 113
	150 ng PbcA(CP1200)*	1,201
	*assayed once	

Rabbit polyclonal antibody prepared against PbcA was used to 35 determine whether the toxicity and IL-8 production stimulated by PbcA was

inhibited by PbcA-specific antibody as confirmation that the effects observed in these studies were attributable to PbcA.

Example 7
PbcA Binds Human C3

5

C3/PbcA ELISA Binding Assay

Purified PbcA was bound to ELISA 8-well strips (Costar, Cambridge, MA) overnight in binding buffer at room temp at varying 10 concentrations (.5 µg/well and 0 µg/well). Wells were blocked with 5% Milk, 0.05% Tween 20 in PBS and 0.02% azide for 2 hours, washed 3 times with 0.05% Tween 20 in PBS and C3 was added (5 µg/well) in antibody diluent buffer (1% BSA, 1% Tween 20 in PBS) for 2 hours at 37°C. Plates were washed 3 times and incubated with HRP-conjugated goat anti-human C3 (1µg/ml) for 1 15 hour at 37°C. Plates were washed 3 times, developed with OPD (Zymed protocol) for 30 minutes, and the absorbence was read at A₄₉₀ on an ELISA plate reader.

A standard curve was prepared to assess saturation of PbcA on the plate. Serial dilutions of PbcA protein were added (from 500 ng/well to 0 20 ng/well) to microtiter wells. Plates were incubated for 1 hour at 37°C with anti-PbcA (1:100), washed, incubated with HRP-conjugated goat anti-rabbit (1:2000) for 1 hour at 37°C. Plates were washed and developed with a 1:10 dilution of OPD developing buffer for 20 minutes at room temperature as per manufacturer's instructions and read at A₄₉₀ on an ELISA plate reader.

25 Binding of C3 was determined by the immobilization of 500 ng PbcA/well. C3 was added in serial dilutions from 10 µg/well to 0 µg/well and incubated with immobilized PbcA for 2 hours at 37°C. Goat HRP-conjugated anti-human C3 (1 µg/well) was added and the absorbance was assessed. Figure 2 shows a dose-response curve for the binding of increasing amounts of C3 to 30 constant amounts of immobilized PbcA.

Results indicated (see Figure 2) that increasing concentrations of C3 bound to 0.5 µg/well PbcA on the plate and saturated with a plateau of 6µg/well.

- Initial blocking experiments were done using the IgG fraction of 5 anti-PbcA polyclonal antibodies (2 to 8-fold molar excess over 500 mg PbcA added per well). The IgG fraction of serum from unimmunized rabbits served as a control. After PbcA protein was bound to the plate overnight and blocked for 2 hours, anti-PbcA antibodies were added for 1 hour at 37°C prior to the addition of C3. Plates were washed, 6 µg C3 was added to each well for 2 hours at 37°C. 10 Plates were then incubated with goat HRP-conjugated anti-human C3 for 1 hour at 37°C then washed and developed for 4 minutes.

Both the IgG fraction of anti-PbcA antibodies and affinity purified antibodies inhibited C3 binding up to 50% while control IgG antibodies did not inhibit C3 binding. Figure 3a (Western blot) demonstrates that the IgG 15 fraction of anti-PbcA blocked the binding of human C3 to PbcA immobilized on nitrocellulose. Figure 3b demonstrates that affinity-purified anti-PbcA blocked the binding of C3 to PbcA by 40-50%, while those antibodies remaining in rabbit serum after the removal of anti-PbcA antibodies had no blocking effect.

20

Example 8

Production of *pbcA* Insertion/Duplication Mutants of *S. Pneumoniae*

Generation of a *pbcA* insertion/duplication construct

To generate an insertion/duplication mutant of *pbcA*, a 761 bp 25 fragment was isolated from pDF145 (a plasmid containing *pbcA*) first by digestion with ApoI (New England Biolabs) followed by the addition of DNA Polymerase I, Large (Klenow) Fragment to create a blunt end, and second by digestion with NheI to create a 5' overhang sticky end compatible with XbaI in the vector pVA891. This vector is a streptococcal/*E. coli* shuttle vector that 30 replicated in *E. coli* but not in *S. pneumoniae* (from Dr. Gary Dunny, Dept. Microbiology, University of Minnesota, Minneapolis, MN and described in Macrina FL, et al. *Gene* 25:145-150, 1983). The 761 bp fragment was isolated on

- a 0.7% agarose gel. Concurrently, the vector pVA891 was digested with *Cla*I and treated with Klenow to create a blunt end, followed by digestion with *Xba*I to create a 5' sticky end. The 761 bp fragment of *pbcA* was ligated into the pneumococcal vector pVA891 and transformed into competent DH5 α *E. coli*.
- 5 Transformants were selected by resistance to chloramphenicol and plasmid DNA from 12 clones was cut with EcoRI and SpeI (the 761 fragment introduced a SpeI site). This confirmed the presence of the insert DNA in clones 2-12 and the absence of the insert in the control vector clone. Clone 4 was selected as construct pBV004 and DNA was transformed into unencapsulated laboratory
- 10 strains R6x and CP1200 and selected by erythromycin (Erm) resistance.

Transformation of Knockout Construct for Insertion/Duplication

Mutagenesis

Pneumococcal strains CP1200 and R6x were grown to OD₅₅₀ = 0.2 and stored as frozen stock aliquots. Pneumococcal cultures were diluted 1:100 to 0.002 and grown to OD₅₅₀ = 0.02. Competence was induced by the Morrison CSP protocol (Haverstein, L. et al. *Proc. Natl. Acad. Sci. (USA)* 92:11140-11144, 1995). To 100 μ l of cells, competence stimulating peptide (CSP) 100ng, was added along with 500ng to about 1 μ g of construct pBV004 DNA. Cells 20 were incubated for 30-40 minutes in a 37°C water bath with aeration to maintain constant temperature. After transformation, cells were diluted 1:10 in one ml total volume of THB+Y. DNase I (10 μ g/ml) was added and cells were incubated an additional 90 minutes to allow integration. The transformation mixture was diluted 1:10 and 100 μ l of cells were plated in a 4-layer agar overlay procedure as follows: first overlay, 3 mls THB agar; second overlay, 1.5 mls THBY + 1.5 mls THB agar + 100 μ l transformation mixture, incubate 1 hour at 37° C; third 25 overlay, 3 mls THB agar; fourth overlay, 3 mls THB agar + .05 μ g/ml Erythromycin.

Genomic DNA was isolated from wild type R6x, CP1200 and 30 BD23(virulent 23F strain *supra*) strains as well as from insertional mutants in R6x and CP1200. Genomic DNA was digested with EcoRI (which does not

cut within the *pbcA* gene) and electrophoresed in 0.7% agarose, blotted onto nylon membrane and Southern blot performed with digoxigenin-labeled probes.

Referring to Figure 5, on the left are the results of a the Southern blot using the 1.5 kb fragment of *pbcA* as the probe. The probe hybridized with 5 wild-type pneumococcal DNA in a single band and hybridized with two bands in the mutants R62r, R63r, R6x5 and CP1r, as expected.

On the right, the same blot was stripped and reprobed with pVA891 vector DNA. Wild-type DNA does not hybridize with pVA891, while the vector probe hybridizes at the same two bands indicating that the insertion 10 mutagenesis was within the *pbcA* gene.

To confirm that the insertion mutated the gene and disrupted protein production, a Western blot analysis was performed (see Figure 6).

On the left, trichloroacetic acid (TCA) precipitated supernatants from strain R6x and the R62r mutant were electrophoresed on a 7.5% SDS-PAGE gel and blotted with either anti-PbcA antibodies and HRP-goat-anti-rabbit antibodies for detection of PbcA or with biotinylated C3 and HRP-avidin for detection of C3 binding. Insertional mutants did not synthesize PbcA and failed to bind to anti-PbcA antibodies or biotinylated C3. Absence of protein and lack of C3 binding was seen in the mutant compared to wild-type. The PbcA 20 protein from R6x is larger than that of CP1200.

25

The original CP1200 detected a 90 kDa protein and had a truncated choline binding region due to premature termination. The R6x PbcA protein was about 105 kDa and appears to contain at least 9 choline binding repeats.

It will be appreciated by those skilled in the art that while the invention has been described above in connection with particular embodiments and examples, the invention is not necessarily so limited and that numerous other embodiments, examples, uses, modifications and departures from the 30 embodiments, examples and uses may be made without departing from the inventive scope of this application.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

5

(i) APPLICANT: REGENTS OF THE UNIVERSITY OF MINNESOTA, ET AL.

(ii) TITLE OF INVENTION: C3 BINDING PROTEIN OF STREPTOCOCCUS
PNEUMONIAE

10

(iii) NUMBER OF SEQUENCES: 12

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: MUETING, RAASCH & GEBHARDT, P.A.

(B) STREET: 119 North Fourth Street, Suite 203

(C) CITY: Minneapolis

(D) STATE: Minnesota

(E) COUNTRY: USA

(F) ZIP: 55401

20

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

25

(D) SOFTWARE: PatentIn Release #1.0, Version #1.30

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: PCT/US97/20586

(B) FILING DATE: 12-NOV-1997

30

(C) CLASSIFICATION:

(vii) PRIORITY APPLICATION DATA:

(A) APPLICATION NUMBER: 60/029,444

(B) FILING DATE: 12-NOV-1996

35

(C) CLASSIFICATION:

(A) APPLICATION NUMBER: 60/038,086

(B) FILING DATE: 18-FEB-1997

(C) CLASSIFICATION:

40

33

- (A) APPLICATION NUMBER: 60/059,368
(B) FILING DATE: 19-SEP-1997
(C) CLASSIFICATION:

5

- (A) APPLICATION NUMBER: 60/062,473
(B) FILING DATE: 16-OCT-1997
(C) CLASSIFICATION

(viii) ATTORNEY/AGENT INFORMATION:

10

- (A) NAME: MCCORMACK, MYRA H.
(B) REGISTRATION NUMBER: 36,602
(C) REFERENCE/DOCKET NUMBER: 110.00430201

15

(ix) TELECOMMUNICATION INFORMATION:

15

- (A) TELEPHONE: 612-305-1225
(B) TELEFAX: 612-305-1228

(2) INFORMATION FOR SEQ ID NO:1:

20

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
25 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

35

Thr Glu Asn Glu Gly Ser Thr Gln Ala Ala Thr Ser Ser Asn Met Ala
1 5 10 15

Lys Thr Glu His

20

40 (2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: peptide

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Glu	Lys	Pro	Ala	Glu	Gln	Pro	Gln	Pro	Ala	Pro	Ala	Thr	Gln	Pro
1				5					10					15

15

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

30

Ser	Ser	Asp	Ser	Ser	Val	Gly	Glu	Glu	Thr	Leu	Pro	Ser	Ser	Leu
1					5				10					15

Lys

35

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3023 base pairs

40

35

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: DNA (genomic)

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

	GTAATACGAC TCACTATAGG GCGAATTGGG TACCGGGCCC CCCCTCGAGG TCGACGGTAT	60
15	CGATAAGCTT ATGCTTGTCA ATAATCACAA ATATGTAGAT CATATCTTGT TTAGGACAGT	120
	AAAACATCCT AATTACTTT TAAATATTCT TCCTGAGTTG ATTGGCTTGA CCTTGTTGAG	180
	TCATGCTTAT GTGACTTTG TTTAGTTT TCCAGTTAT GCAGTTATTT TGTATCGACG	240
20	AATAGCTGAA GAGGAAAAGC TATTACATGA AGTTATAATC CCAAATGGAA GCATAAAAGAG	300
	ATAAAATACAA AATTGATTT ATATACAGTT CATATTGAAG TAATATAGTA AGGTTAAAGA	360
25	AAAAATATAG AAGGAAATAA ACATGTTGC ATCAAAAAGC GAAAGAAAAG TACATTATTC	420
	AATTCGTAAA TTTAGTATTG GAGTAGCTAG TGTAGCTGTT GCCAGTCTTG TTATGGGAAG	480
	TGTGGTTCAT GCGACAGAGA ACGAGGGAAG TACCCAAGCA GCCACTTCTT CTAATATGGC	540
30	AAAGACAGAA CATAGGAAAG CTGCTAAACA AGTCGTCGAT GAATATATAG AAAAAATGTT	600
	GAGGGAGATT CAACTAGATA GAAGAAAACA TACCCAAAAT GTCGCCTTAA ACATAAAAGTT	660
35	GAGCGCAATT AAAACGAAGT ATTTGCGTGA ATTAAATGTT TTAGAAAGAGA AGTCGAAAGA	720
	TGAGTTGCCG TCAGAAATAA AAGCAAAGTT AGACGCAGCT TTTGAGAAGT TTAAAAAAAGA	780
	TACATTGAAA CCAGGAGAAA AGGTAGCAGA AGCTAAGAAG AAGGTTGAAG AAGCTAAGAA	840
40	AAAAGCCGAG GATCAAAAAG AAGAAGATCG TCGTAACTAC CCAACCAATA CTTACAAAAC	900

	GCTTGAACCTT GAAATTGCTG AGTCGATGT GAAAGTTAAA GAAGCGGAGC TTGAACTAGT	960
	AAAAGAGGAA GCTAAAGAAT CTCGAAACGA GGGCACATT AAGCAAGCAA AAGAGAAAAGT	1020
5	TGAGAGTAAA AAAGCTGAGG CTACAAGGTT AGAAAACATC AAGACAGATC GTAAAAAAAGC	1080
	AGAAGAAGAA GCTAAACGAA AAGCAGATGC TAAGTTGAAG GAAGCTAATG TAGCGACTTC	1140
	AGATCAAGGT AAACCAAAGG GGCGGGCAAA ACGAGGAGTT CCTGGAGAGC TAGAACACCC	1200
10	TGATAAAAAA GAAAATGATG CGAAAGTCTTC AGATTCTAGC GTAGGTGAAG AAACCTTCC	1260
	AAGCTCATCC CTGAAATCAG GAAAAAAGGT AGCAGAAGCT GAGAAGAAGG TTGAAGAAGC	1320
15	TGAGAAAAAA GCCAAGGATC AAAAAGAAGA AGATGCCGT AACTACCCAA CCAATACTTA	1380
	CAAAACGCTT GACCTTGAAA TTGCTGAGTC CGATGTGAAA GTTAAAGAAG CGGAGCTTGA	1440
	ACTAGTAAAA GAGGAAGCTA AGGAACCTCG AGACGAGGAA AAAATTAAGC AAGCAAAAGC	1500
20	GAAAGTTGAG AGTAAAAAAG CTGAGGCTAC AAGGTTAGAA AACATCAAGA CAGATCGTAA	1560
	AAAAGCAGAA GAAGAAGCTA AACGAAAAGC AGCAGAAGAA GATAAAGTT AAGAAAAACC	1620
25	AGCTGAACAA CCACAACCAG CGCCGGCTAC TCAACCAGAA AAACCAGCTC CAAAACCAGA	1680
	GAAGCCAGCT GAACAACCAA AAGCAGAAAA AACAGATGAT CAACAAGCTG AAGAAGACTA	1740
	TGCTCGTACA TCAGAAGAAG AATATAATCG CTTGACTCAA CAGCAACCGC CAAAAACTGA	1800
30	AAAACCAGCA CAACCATCTA CTCCAAAAAC AGGCTGGAAA CAAGAAAACG GTATGTGGTA	1860
	CTTCTACAAT ACTGATGGTT CAATGGCAAC AGGATGGCTC CAAAACAACG GTTCATGGTA	1920
35	CTATCTAAC GCTAATGGTG CTATGGCGAC AGGATGGCTC CAAAACAATG GTTCATGGTA	1980
	CTATCTAAC GCTAATGGTT CAATGGCAAC AGGATGGCTC CAAAACAATG GTTCATGGTA	2040
	CTACCTAAC GCTAATGGTG CTATGGCGAC AGGATAGCTC CAATACAATG GTTCATGGTA	2100
40		

	CTACCTAAC AGCAATGGCG CTATGGCGAC AGGATGGCTC CAATACAATG GTCATGGTA	2160
	CTACCTCAAC GCTAATGGTG ATATGGCGAC AGGATGGCTC CAAAACAACG GTTCATGGTA	2220
5	CTACCTCAAC GCTAATGGTG ATATGGCGAC AGGATGGCTC CAATACAACG GTTCATGGTA	2280
	TTACCTCAAC GCTAATGGTG ATATGGCGAC AGGTTGGGTG AAAGATGGAG ATACCTGGTA	2340
10	CTATCTGAA GCATCAGGTG CTATGAAAGC AAGCCAATGG TTCAAAGTAT CAGATAAATG	2400
	GTACTATGTC AATGGCTCAG GTGCCCTTGC AGTCAACACA ACTGTAGATG GCTATGGAGT	2460
	CAATGCCAAT GGTGAATGGG TAAACTAAC CTAATATAAC TAGTTAATAC TGACTTCCTG	2520
15	TAAGAACTTT TTAAAGTATT CCCTACAAAT ACCATATCCT TTCAGTAGAT AATATACCT	2580
	TGTAGGAAGT TTAGATTAAA AAATAACTCT GTAATCTCTA GCCGGATTTA TAGCGCTAGA	2640
20	GACTACGGAG TTTTTTGAT GAGGAAAGAA TGGCGGCATT CAAGAGACTC TTTAAGAGAG	2700
	TTACGGGTTT TAAACTATTA AGCCTCTCC AATTGCAAGA GGGCTCAAT CTCTGCTAGG	2760
	GTGCTAGCTT GCGAAATGGC TCCACGGAGT TTGGCAGCGC CAGATGTTCC ACGGAGATAG	2820
25	TGAGGAGCGA GGCGCGGAA TTCACGAAC GCGACGTTTT CTCCTTGAG GTTAATCAAT	2880
	CGTTTCAGGA ATTCCGGAAT TCCGGAATTC CGGAATTCCG GAATTCCGGA ATTCCCTGCAG	2940
30	CCCGGGGGAT CCACTAGTTC TAGAGCGGCC GCCACCGCGG TGGAGCTCCA GCTTTGTT	3000
	CCTTTAGTGA GGGTTAATTT CGA	3023

(2) INFORMATION FOR SEQ ID NO:5:

35 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1695 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

	CGAAACGAGG GCACAATTAA GCAAGCAAAA GAGAAAGTTG AGAGTAAAAA AGCTGAGGCT	60
10	ACAAGGTTAG AAAACATCAA GACAGATCGT AAAAAAGCAG AAGAAGAAGC TAAACGAAA	120
	GCAGATGCTA AGTTGAAGGA AGCTAATGTA GCGACTTCAG ATCAAGGTAA ACCAAAGGGG	180
	CGGGCAAAAC GAGGAGTTCC TGGAGAGCTA GCAACACCTG ATAAAAAAGA AAATGATGCG	240
15	AAGTCTTCAG ATTCTAGCGT AGGTGAAGAA ACTCTTCAA GCTCATCCCT GAAATCAGGA	300
	AAAAAGGTAG CAGAACGCTGA GAAGAAGGTT GAAGAAGCTG AGAAAAAAGC CAAGGATCAA	360
20	AAAGAAGAAG ATCGCCGTAA CTACCCAACC AATACTTACA AAACGCTTGA CCTTGAAATT	420
	GCTGAGTCCG ATGTGAAAGT TAAAGAAGCG GAGCTTGAAC TAGTAAAAGA GGAAGCTAAG	480
	GAACCTCGAG ACGAGGAAAA AATTAAGCAA GCAAAAGCGA AAGTTGAGAG TAAAAAAGCT	540
25	GAGGCTACAA GTTAGAAAA CATCAAGACA GATCGTAAA AAGCAGAAGA AGAAGCTAAA	600
	ATGTTGCAT CAAAAAGCGA AAGAAAAGTA CATTATTCAA TTCTGAAATT TAGTATTGGA	660
30	GTAGCTAGTG TAGCTGTTGC CAGTCTTGTG ATGGGAAGTG TGGTCATGC GACAGAGAAC	720
	GAGGGAAGTA CCCAAGCAGC CACTCTTCT AATATGGCAA AGACAGAACAA TAGGAAAGCT	780
	GCTAAACAAG TCGTCGATGA ATATATAGAA AAAATGTTGA GGGAGATTCA ACTAGATAGA	840
35	AGAAAACATA CCCAAATGT CGCCTTAAAC ATAAAGTTGA GCGCAATTAA AACGAAGTAT	900
	TTGCGTGAAT TAAATGTTT AGAACAGAAC TCGAAAGATG AGTTGCCGTC AGAAATAAAA	960
40	GCAAAGTTAG ACGCAGCTTT TGAGAAGTTT AAAAAAGATA CATTGAAACC AGGAGAAAAG	1020

	GTAGCAGAAG CTAAGAAGAA GGTTGAAGAA GCTAAGAAAA AAGCCGAGGA TCAAAAAGAA	1080
	GAAGATCGTC GTAAC TACCC AACCAATACT TACAAAACGC TTGAAC TTGA AATTGCTGAG	1140
5	TTCGATGTGA AAGTTAAAGA AGCGGAGCTT GAACTAGTAA AAGAGGAAGC TAAAGAATCT	1200
	CGAAAAGCAG CAGAAGAAGA TAAAGTTAAA GAAAAACCAG CTGAACAACC ACAACCAGCG	1260
10	CCGGCTACTC AACCAGAAAA ACCAGCTCCA AAACCAGAGA AGCCAGCTGA ACAACCAAAA	1320
	GCAGAAAAAA CAGATGATCA ACAAGCTGAA GAAGACTATG CTCGTAGATC AGAAGAAGAA	1380
	TATAATCGCT TGACTCAACA GCAACCGCCA AAAACTGAAA AACCAAGCACA ACCATCTACT	1440
15	CCAAAAAACAG GCTGGAAACA AGAAAACGGT ATGTGGTACT TCTACAATAC TGATGGTTCA	1500
	ATGGCAACAG GATGGCTCCA AAACAACGGT TCATGGTACT ATCTAAACGC TAATGGTGCT	1560
20	ATGGCGACAG GATGGCTCCA AAACAATGGT TCATGGTACT ATCTAAACGC TAATGGTTCA	1620
	ATGGCAACAG GATGGCTCCA AAACAATGGT TCATGGTACT ACCTAAACGC TAATGGTGCT	1680
	ATGGCGACAG GATAG	1695

25 (2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 564 amino acids
- (B) TYPE: amino acid
- 30 (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

40

40

	Phe Asp Val Lys Val Lys Glu Ala Glu Leu Glu Leu Val Lys Glu Glu			
1	5	10	15	
	Ala Lys Glu Ser Arg Asn Glu Gly Thr Ile Lys Gln Ala Lys Glu Lys			
5	20	25	30	
	Val Glu Ser Lys Lys Ala Glu Ala Thr Arg Leu Glu Asn Ile Lys Thr			
	35	40	45	
10	Asp Arg Lys Lys Ala Glu Glu Ala Lys Arg Lys Ala Asp Ala Lys			
	50	55	60	
	Leu Lys Glu Ala Asn Val Ala Thr Ser Asp Gln Gly Lys Pro Lys Gly			
	65	70	75	80
15	Arg Ala Lys Arg Gly Val Pro Gly Glu Leu Ala Thr Pro Asp Lys Lys			
	85	90	95	
20	Glu Asn Asp Ala Lys Ser Ser Asp Ser Ser Val Gly Glu Glu Thr Leu			
	100	105	110	
	Pro Ser Ser Ser Leu Lys Ser Gly Lys Lys Val Ala Glu Ala Glu Lys			
	115	120	125	
25	Lys Val Glu Glu Ala Glu Lys Lys Ala Lys Asp Gln Lys Glu Glu Asp			
	130	135	140	
	Arg Arg Asn Tyr Pro Thr Asn Thr Tyr Lys Thr Leu Asp Leu Glu Ile			
	145	150	155	160
30	Ala Glu Ser Asp Val Lys Val Lys Glu Ala Glu Leu Glu Ile Val Lys			
	165	170	175	
	Glu Glu Ala Lys Glu Pro Arg Asp Glu Glu Lys Ile Lys Gln Ala Lys			
	180	185	190	
35	Ala Lys Val Glu Ser Lys Lys Ala Glu Ala Thr Arg Leu Glu Asn Ile			
	195	200	205	
	Lys Thr Asp Arg Lys Lys Ala Glu Glu Ala Lys Met Phe Ala Ser			
40	210	215	220	

41

Lys Ser Glu Arg Lys Val His Tyr Ser Ile Arg Lys Phe Ser Ile Gly
 225 230 235 240

5 Val Ala Ser Val Ala Val Ala Ser Leu Val Met Gly Ser Val Val His
 245 250 255

Ala Thr Glu Asn Glu Gly Ser Thr Gln Ala Ala Thr Ser Ser Asn Met
 260 265 270

10 Ala Lys Thr Glu His Arg Lys Ala Ala Lys Gln Val Val Asp Glu Tyr
 275 280 285

Ile Glu Lys Met Leu Arg Glu Ile Gln Leu Asp Arg Arg Lys His Thr
 290 295 300

15 Gln Asn Val Ala Leu Asn Ile Lys Leu Ser Ala Ile Lys Thr Lys Tyr
 305 310 315 320

20 Leu Arg Glu Leu Asn Val Leu Glu Glu Lys Ser Lys Asp Glu Leu Pro
 325 330 335

Ser Glu Ile Lys Ala Lys Leu Asp Ala Ala Phe Glu Lys Phe Lys Lys
 340 345 350

25 Asp Thr Leu Lys Pro Gly Glu Lys Val Ala Glu Ala Lys Lys Lys Val
 355 360 365

Glu Glu Ala Lys Lys Ala Glu Asp Gln Lys Glu Glu Asp Arg Arg
 370 375 380

30 Asn Tyr Pro Thr Asn Thr Tyr Lys Thr Leu Glu Leu Glu Ile Ala Glu
 385 390 395 400

35 Arg Lys Ala Ala Glu Glu Asp Lys Val Lys Glu Lys Pro Ala Glu Gln
 405 410 415

Pro Gln Pro Ala Pro Ala Thr Gln Pro Glu Lys Pro Ala Pro Lys Pro
 420 425 430

40

42

Glu Lys Pro Ala Glu Gln Pro Lys Ala Glu Lys Thr Asp Asp Gln Gln
435 440 445

5 Ala Glu Glu Asp Tyr Ala Arg Arg Ser Glu Glu Glu Tyr Asn Arg Leu
450 455 460

Thr Gln Gln Gln Pro Pro Lys Thr Glu Lys Pro Ala Gln Pro Ser Thr
465 470 475 480

10 Pro Lys Thr Gly Trp Lys Gln Glu Asn Gly Met Trp Tyr Phe Tyr Asn
485 490 495

Thr Asp Gly Ser Met Ala Thr Gly Trp Leu Gln Asn Asn Gly Ser Trp
500 505 510

15 Tyr Tyr Leu Asn Ala Asn Gly Ala Met Ala Thr Gly Trp Leu Gln Asn
515 520 525

20 Asn Gly Ser Trp Tyr Tyr Leu Asn Ala Asn Gly Ser Met Ala Thr Gly
530 535 540

Trp Leu Gln Asn Asn Gly Ser Trp Tyr Tyr Leu Asn Ala Asn Gly Ala
545 550 555 560

25 Met Ala Thr Gly

(2) INFORMATION FOR SEQ ID NO:7:

30 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

35 (ii) MOLECULE TYPE: DNA (genomic)

40

43

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

GCACAAACCAT CTACTCCA

18

5 (2) INFORMATION FOR SEO ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8.

20 GTACAGGAAT TCACCTATTAA GTC

23

(2) INFORMATION FOR SEO ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 220 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: protein

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3

40

44

Gly Ser Met Ala Thr Gly Trp Leu Gln Asn Asn Gly Ser Trp Tyr Tyr
 20 25 30

5
 Leu Asn Ala Asn Gly Ala Met Ala Thr Gly Trp Leu Gln Asn Asn Gly
 35 40 45

Ser Trp Tyr Tyr Leu Asn Ala Asn Gly Ser Met Ala Thr Gly Trp Leu
 50 55 60

10 Gln Asn Asn Gly Ser Trp Tyr Tyr Leu Asn Ala Asn Gly Ala Met Ala
 65 70 75 80

Thr Gly Leu Gln Tyr Asn Gly Ser Trp Tyr Tyr Leu Asn Ser Asn Gly
 85 90 95

15 Ala Met Ala Thr Gly Trp Leu Gln Tyr Asn Gly Ser Trp Tyr Tyr Leu
 100 105 110

20 Asn Ala Asn Gly Asp Met Ala Thr Gly Trp Leu Gln Asn Asn Gly Ser
 115 120 125

Trp Tyr Tyr Leu Asn Ala Asn Gly Asp Met Ala Thr Gly Trp Leu Gln
 130 135 140

25 Tyr Asn Gly Ser Trp Tyr Tyr Leu Asn Ala Asn Gly Asp Met Ala Thr
 145 150 155 160

Gly Trp Val Lys Asp Gly Asp Thr Trp Tyr Tyr Leu Glu Ala Ser Gly
 165 170 175

30 Ala Met Lys Ala Ser Gln Trp Phe Lys Val Ser Asp Lys Trp Tyr Tyr
 180 185 190

35 Val Asn Gly Ser Gly Ala Leu Ala Val Asn Thr Thr Val Asp Gly Tyr
 195 200 205

Gly Val Asn Ala Asn Gly Glu Trp Thr Lys His Tyr
 210 215 220

40 (2) INFORMATION FOR SEQ ID NO:10:

45

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 217 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- 5 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

15 Lys Gln Glu Asn Gly Met Trp Tyr Phe Tyr Asn Thr Asp Gly Ser Met
 1 5 10 15

Ala Thr Gly Trp Leu Gln Asn Asn Gly Ser Trp Tyr Tyr Leu Asn Ala
 20 25 30

20 Asn Gly Ala Met Ala Thr Gly Trp Leu Gln Asn Asn Gly Ser Trp Tyr
 35 40 45

25 Tyr Leu Asn Ala Asn Gly Ser Met Ala Thr Gly Trp Leu Gln Asn Asn
 50 55 60

Gly Ser Trp Tyr Tyr Leu Asn Ala Asn Gly Ala Met Ala Thr Gly Trp
 65 70 75 80

30 Leu Gln Tyr Asn Gly Ser Trp Tyr Tyr Leu Asn Ser Asn Gly Ala Met
 85 90 95

Ala Thr Gly Trp Leu Gln Tyr Asn Gly Ser Trp Tyr Tyr Leu Asn Ala
 100 105 110

35 Asn Gly Asp Met Ala Thr Gly Trp Leu Gln Asn Asn Gly Ser Trp Tyr
 115 120 125

Tyr Leu Asn Ala Asn Gly Asp Met Ala Thr Gly Trp Leu Gln Tyr Asn
 130 135 140

40

WO 98/21337

46

Gly Ser Trp Tyr Tyr Leu Asn Ala Asn Gly Asp Met Ala Thr Gly Trp
 145 150 155 160

Val Lys Asp Gly Asp Thr Trp Tyr Tyr Leu Glu Ala Ser Gly Ala Met
 165 170 175

5

Lys Ala Ser Gln Trp Phe Lys Val Ser Asp Lys Trp Tyr Tyr Val Asn
 180 185 190

10

Gly Ser Gly Ala Leu Ala Val Asn Thr Thr Val Asp Gly Tyr Gly Val
 195 200 205

Asn Ala Asn Gly Glu Trp Thr Lys Pro
 210 215

15

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 220 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

30

Leu Glu Thr Arg Asn Gly Met Trp Tyr Phe Tyr Asn Thr Asp Gly Ser
 1 5 10 15

35

Met Ala Thr Gly Trp Leu Gln Asn Asn Gly Ser Trp Tyr Tyr Leu Asn
 20 25 30

Ser Asn Gly Ala Met Ala Thr Gly Trp Leu Gln Asn Asn Gly Ser Trp
 35 40 45

40

47

Tyr Tyr Leu Asn Ala Asn Gly Ser Met Ala Thr Gly Trp Leu Gln Asn
 50 55 60

Asn Gly Ser Trp Tyr Tyr Leu Asn Ala Asn Gly Ala Met Ala Thr Gly
 5 65 70 75 80

Trp Leu Gln Tyr Asn Gly Ser Trp Tyr Tyr Leu Asn Ser Asn Gly Ala
 85 90 95

10 Met Ala Thr Gly Trp Leu Gln Tyr Asn Gly Ser Trp Tyr Tyr Leu Asn
 100 105 110

Ala Asn Gly Asp Met Ala Thr Gly Trp Leu Gln Asn Asn Gly Ser Trp
 15 115 120 125

Tyr Tyr Leu Asn Ala Asn Gly Asp Met Ala Thr Gly Trp Leu Gln Tyr
 130 135 140

20 Asn Gly Ser Trp Tyr Tyr Leu Asn Ala Asn Gly Asp Met Ala Thr Gly
 145 150 155 160

Trp Val Lys Asp Gly Asp Thr Trp Tyr Tyr Leu Glu Ala Ser Gly Ala
 165 170 175

25 Met Lys Ala Ser Gln Trp Phe Lys Val Ser Asp Lys Trp Tyr Tyr Val
 180 185 190

Asn Gly Ser Gly Ala Leu Ala Val Asn Thr Thr Val Asp Gly Tyr Gly
 30 195 200 205

Val Asn Ala Asn Gly Glu Trp Thr Lys Pro Asn Ile
 210 215 220

(2) INFORMATION FOR SEQ ID NO:12:

35

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

40

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

WHAT IS CLAIMED IS:

1. An isolated protein comprising SEQ ID NO:1 and at least two choline binding repeats.
2. The protein of claim 1 wherein the protein is isolated from *S. pneumoniae*.
3. The protein of claim 1 wherein the protein binds human complement protein C3.
4. The protein of claim 1, wherein the protein is a recombinant protein.
5. The protein of claim 1 having a molecular weight as determined on a 15% polyacrylamide gel of between about 90 kDa to about 110 kDa.
6. The protein of claim 1 further comprising a proline rich region.
7. The protein of claim 1 further comprising SEQ ID NO:2 or SEQ ID NO:3.
8. An isolated protein comprising SEQ ID NO:6.
9. An isolated protein capable of binding to, but not cleaving or degrading, human complement C3 and wherein the protein comprises SEQ ID NO:1.
10. The protein of claim 9 wherein the protein is isolated from *S. pneumoniae*.
11. The protein of claim 9 further comprising a proline rich region.

12. The protein of claim 9 further comprising SEQ ID NO:2.
13. The protein of claim 9 having at least about 95% homology to a C3 binding protein from *S. pneumoniae*.
14. The protein of claim 9 having a molecular weight as determined on a 15% polyacrylamide gel of between about 90 kDa to about 110 kDa.
15. The protein of claim 9, wherein the protein is a recombinant protein.
16. A recombinant protein comprising SEQ ID NO:1, wherein the protein has a molecular weight as determined on a 15% polyacrylamide gel of between about 90 kDa to about 110 kDa.
17. The protein of claim 16 wherein the protein binds human complement protein C3.
18. The protein of claim 16 further comprising a proline rich region.
19. The protein of claim 17, wherein the protein does not cleave or degrade human complement protein C3.
20. A protein comprising amino acids 1-410 of SEQ ID NO:6.
21. A protein that binds, but does not cleave or degrade, human complement protein C3, wherein nucleic acid encoding the protein hybridizes to SEQ ID NO:4 under hybridization conditions of 6XSSC, 5X Denhardt, 0.5% SDS, and 100 µg/ml fragmented and denatured salmon sperm DNA hybridized overnight at 65°C and washed in 2X SSC, 0.1% SDS one time at room temperature for about 10 minutes followed by one time at, 65°C for about 15 minutes followed

by at least one wash in 0.2XSSC, 0.1% SDS at room temperature for at least 3-5 minutes.

22. The protein of claim 21 further comprising SEQ ID NO:1.
23. The protein of claim 21 further comprising SEQ ID NO:2 or SEQ ID NO:3.
24. The protein of claim 21 wherein the protein is at least 15 amino acids in length.
25. The protein of claim 21, wherein the protein is a recombinant protein.
26. The protein of claim 21 further comprising a proline rich region.
27. The protein of claim 21, wherein the protein is a synthetic peptide.
28. The protein of claim 21, wherein the protein is a peptide of at least 15 amino acids from SEQ ID NO:6.
29. Antibody capable of specifically binding to the protein of claim 21.
30. The antibody of claim 29, wherein the antibody is a monoclonal antibody.
31. The antibody of claim 29, wherein the antibody is a polyclonal antibody.
32. The antibody of 30, wherein the antibody is rodent-derived.
33. Nucleic acid encoding a protein comprising at least two choline binding domains and SEQ ID NO: 1.

34. The nucleic acid of claim 33 further comprising a proline rich region.
35. The nucleic acid of claim 33 isolated from an *S. pneumoniae* genome.
36. The nucleic acid of claim 33 capable of hybridizing to SEQ ID NO:4.
37. The nucleic acid of claim 33 wherein the protein encoded by the nucleic acid binds to human complement protein C3.
38. The nucleic acid of claim 33 in a nucleic acid vector.
39. The nucleic acid of claim 33 wherein the vector is an expression vector.
40. The nucleic acid of claim 38 in a cell.
41. The nucleic acid of claim 40 wherein the cell is a bacterium.
42. A bacterium expressing a recombinant protein according to claim 21.
43. The nucleic acid of claim 39 in a cell.
44. Protein produced by the nucleic acid of claim 43.
45. Isolated nucleic acid encoding a protein comprising SEQ ID NO:1 and a proline rich region wherein the protein encoded by the nucleic acid binds but does not cleave or degrade human complement C3.
46. An isolated nucleic acid fragment encoding an about 90 kDa to about 110 kDa protein with C3 binding activity, wherein the nucleic acid fragment has at least 80% homology to at least 500 bp from nucleic acids 1-1500 of SEQ ID NO:5.

47. An isolated nucleic acid fragment comprising base pairs 1-1500 of SEQ ID NO:5.
48. A method for isolating a C3 binding protein from a bacterium comprising the steps of:
- obtaining a protein sample from a bacterium;
 - applying the sample to a solid support comprising methylamine treated complement protein C3;
 - washing the solid support; and
 - removing a C3 binding protein from the solid support in a solution comprising alcohol;
- wherein the C3 binding protein does not cleave or degrade C3.
49. The method of claim 48 wherein the bacterium is *S. pneumoniae*.
50. The method of claim 48 wherein the bacterium is *E. coli*.
51. The method of claim 48 wherein the solid support comprises an affinity column.
52. The method of claim 48 wherein the alcohol is ethanol.
53. The method of claim 52 wherein the solution comprising alcohol is a buffer comprising 20% ethanol.
54. C3 binding protein preparable by the method of claim 48.
55. A method for producing an immune response to *S. pneumoniae* comprising the steps of:
- administering a therapeutically effective amount of at least a portion of a protein to a mammal, wherein the protein binds but

does not cleave or degrade human complement protein C3 and, wherein nucleic acid encoding the protein hybridizes to SEQ ID NO:4 under hybridization conditions of 6XSSC, 5X Denhardt, 0.5% SDS, and 100 µg/ml fragmented and denatured salmon sperm DNA, hybridized overnight at 65°C and washed in 2x SSC, 0.1% SDS one time at room temperature for about 10 minutes followed by one time at 65°C for about 15 minutes followed by at least one wash in 0.2xSSC, 0.1% SDS at room temperature for at least 3-5 minutes; and detecting an immune response to the protein.

56. The method of claim 55 wherein the protein is at least 15 amino acids in length.

57. The method of claim 55 wherein the protein is a chimeric protein.

58. The method of claim 55 wherein the protein comprises SEQ ID NO:1.

59. The method of claim 55 wherein the protein has a molecular weight on a 15% polyacrylamide gel of between about 90 kDa to about 110 kDa.

60. A method for reducing *S. pneumoniae* binding to C3 comprising the steps of: administering a therapeutically effective amount of at least a portion of an antibody to a mammal, wherein the antibody specifically recognizes a C3 binding protein from *S. pneumoniae*, and wherein the C3 binding protein is a protein that binds, but does not cleave or degrade human complement protein C3.

61. The method of claim 60 wherein the antibody comprises at least one variable domain from a monoclonal antibody.

62. The method of claim 60 wherein the antibody is administered to the air passages of the mammal.

63. The method of claim 60 wherein the antibody is administered intravenously to a mammal.

64. A non-naturally occurring *S. pneumoniae* bacterium that does not express a detectable human complement C3 binding protein, wherein the C3 binding protein comprises SEQ ID NO:1.

65. The bacterium of claim 64 wherein the bacterium is the product of an insertion into the gene encoding the C3 binding protein.

66. The bacterium of claim 64 wherein the bacterium is a product of a deletion in the gene encoding the C3 binding protein.

67. The bacterium of claim 64 produced by homologous recombination of the gene encoding the C3 binding protein gene with at least a portion of a non-native C3 binding protein gene.

68. The method of claim 67 wherein the gene encoding at least a portion of the non-native C3 binding protein comprises a mutation within the non-native gene.

1/7


			50		
1	DRWKQENG MW	YFYNTDGSMA	TGWLQNNGSW	YYLNANGAMA	TGWLQNNGSW
1200	--KQENG MW	YFYNTDGSMA	TGWLQNNGSW	YYLNANGAMA	TGWLQNNGSW
r6x	--LETTRNG MW	YFYNTDGSMA	TGWLQNNGSW	YYLNANGAMA	TGWLQNNGSW
23F					
			100		
51	YYLNANGSMA	TGWLQNNGSW	YYLNANGAMA	TG*LOYNGSW	YYLNNSNGAMA
1200	YYLNANGSMA	TGWLQNNGSW	YYLNANGAMA	TGWLQYNGSW	YYLNNSNGAMA
r6x	YYLNANGSMA	TGWLQNNGSW	YYLNANGSMA	TGWLQYNGSW	YYLNANGDMA
23F					
			150		
101	TGWLQYNGSW	YYLNANGDMA	TGWLQNNGSW	YYLNANGDMA	TGWLQYNGSW
1200	TGWLQYNGSW	YYLNANGDMA	TGWLQNNGSW	YYLNANGDMA	TGWLQYNGSW
r6x	TGWLQYNGSW	YYLNANGDMA	TGWLQNNGSW	YYLNANGDMA	TGWLQYNGSW
23F					
			200		
151	YYLNANG DMA	TGWVKDGDTW	YYLEASGAMK	ASQWFKVSDK	WYYVNGSGAL
1200	YYLNANG DMA	TGWVKDGDTW	YYLEASGAMK	ASQWFKVSDK	WYYVNGSGAL
r6x	YYLNANG DMA	TGWVKDGDTW	YYLEASGAMK	ASQWFKVSDK	WYYVNGSGAL
23F					
			223		
201	AVNTTVDG YC	VNANGEW * TK	H * Y		
1200	AVNTTVDG YC	VNANGEW * TK	P--		
r6x	AVNTTVDG YC	VNANGEW * TK	PNI		
23F					

Fig. 1

2/7

PbcA Binds C3 in ELISA

Saturation of C3 Binding



3/7




Fig. 3a

SUBSTITUTE SHEET (RULE 26)

4/7

*Anti-PbcA Inhibits Binding of C3 in
Western and ELISA*





Fig. 3B

5/7



7/9




Fig. 5a
Fig. 5b

7/7




Fig. 6b

Fig. 6a

INTERNATIONAL SEARCH REPORT

Intern. Application No
PCT/US 97/20586

A. CLASSIFICATION OF SUBJECT MATTER					
IPC 6	C12N15/31	C12N1/21	C07K14/315	C07K16/12	A61K39/09

A61K39/40 // (C12N1/21, C12R1:46)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 97 41151 A (UNIV ROCKEFELLER) 6 November 1997 see page 9, line 11 - line 19 see page 67, line 14 - line 25 see page 73, line 18 - page 74, line 8 SEQ ID no.24,25 see page 76, line 15 - page 78, line 13; claims 1-40 ---	1-68
A	EP 0 622 081 A (UAB RESEARCH FOUNDATION) 2 November 1994 see the whole document ---	1-68
A	WO 93 24000 A (YOTHER JANET) 9 December 1993 see the whole document --- -/-	1-68

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

8 May 1998

Date of mailing of the international search report

02.06.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hornig, H

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/20586

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	ANONYMOUS: "A C3 - binding protein from Streptococcus pneumoniae." 97TH GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY, MIAMI BEACH, FLORIDA, USA, MAY 4-8, 1997. ABSTRACTS OF THE GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY 97 (0). 1997. 110. ISSN: 1060-2011, XP002064458 Accession no. B-478 ---	1-28, 33-47
P,X	C. ROSENOW ET AL.: "Contribution of novel choline-binding proteins to adherence, colonization and immunogenicity of Streptococcus pneumoniae" EMBL SEQUENCE DATABASE, 29 September 1997, HEIDELBERG, FRG, XP002064459 Accession no. AF019904; AC 030874; ---	1-28, 33-47
P,X	S. HAMMERSCHMIDT ET AL.: "SpsA, a novel pneumococcal surface protein with specific binding to immunoglobulin A and secretory components" EMBL SEQUENCE DATABASE, 14 October 1997, HEIDELBERG, FRG, XP002064460 Accession no. AJ002054 -----	1-28, 33-47

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 97/20586

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 55-63 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/US 97/20586

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9741151	A 06-11-1997	AU	2818297 A	19-11-1997
EP 0622081	A 02-11-1994	AU	682018 B	18-09-1997
		AU	5769694 A	27-10-1994
		CA	2116261 A	21-10-1994
		FI	941695 A	21-10-1994
		JP	7126291 A	16-05-1995
		NO	941420 A	21-10-1994
		US	5679768 A	21-10-1997
		ZA	9401584 A	12-10-1994
WO 9324000	A 09-12-1993	AU	4400293 A	30-12-1993